

FISH & RICHARDSON P.C.

225 Franklin Street
Boston, Massachusetts
02110-2804

Telephone
617 542-5070

Facsimile
617 542-8906

Web Site
www.fr.com



Frederick P. Fish
1855-1930

W.K. Richardson
1859-1951

January 5, 1999

Attorney Docket No.: 10217/250003



Box Patent Application

Assistant Commissioner for Patents
Washington, DC 20231

Presented for filing is a new divisional patent application of:

Applicant: STEVEN M. REPPERT AND TAKASHI EBISAWA
Title: HIGH-AFFINITY MELATONIN RECEPTOR AND USES
THEREOF

BOSTON
NEW YORK
SILICON VALLEY
SOUTHERN CALIFORNIA
TWIN CITIES
WASHINGTON, DC

The prior application is assigned of record to The General Hospital Corporation, a Massachusetts corporation, by virtue of an assignment submitted to the Patent and Trademark Office for recording on November 6, 1995 at 7712/0625 and 7712/0633.

Enclosed are the following papers, including those required to receive a filing date under 37 CFR §1.53(b):

	<u>Pages</u>
Specification	62
Claims	7
Abstract	1
Declaration	2
Drawing(s)	48

Enclosures:

- Preliminary amendment with corrected Cover Sheet, 3 pages.
- Postcard.

"EXPRESS MAIL" Mailing Label Number EL010098256US

Date of Deposit January 5, 1999
I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Paul Gray
USA 6 Gray

FISH & RICHARDSON P.C.

January 5, 1999
Page 2

This application is a divisional (and claims the benefit of priority under 35 USC 120) of U.S. application serial no. 08/466,103, filed June 6, 1995, which application is a continuation-in-part of U.S. Application Serial No. 08/319,887, filed October 7, 1994, now abandoned, which application is a continuation in-part of U.S. Application Serial No. 08/261,857, filed June 17, 1994, now abandoned. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.

The filing fee based on claims remaining after entry of the enclosed preliminary amendment is calculated below:

Basic filing fee	760.00
Total claims in excess of 20 times \$18.00	0.00
Independent claims in excess of 3 times \$78.00	546.00
Fee for multiple dependent claims	0.00
Total filing fee:	\$ 1306.00

Under 37 CFR §1.53(d), no filing fee is being paid at this time. Please apply any other required fees, **EXCEPT FOR THE FILING FEE**, to Deposit Account No. 06-1050, referencing the attorney docket number shown above.


If this application is found to be incomplete, or if a telephone conference would otherwise be helpful, please call the undersigned at 617/542-5070.

Kindly acknowledge receipt of this application by returning the enclosed postcard.

Please send all correspondence to:

Janis K. Fraser, Ph.D., J.D.
Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

Respectfully submitted,


Janis K. Fraser, Ph.D., J.D.
Reg. No. 34,819

Enclosures
348324.B11

PATENT
ATTORNEY DOCKET NO. 10217/250003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Steven M. Reppert et al. Art Unit:
Serial No.: Examiner:
Filed : January 5, 1999
Title : HIGH-AFFINITY MELATONIN RECEPTOR AND USES THEREOF

Assistant Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Specification:

On the cover page for the specification, please insert Takashi Ebisawa as a second inventor beneath the name of Steven M. Reppert. A new, replacement cover page indicating this change is enclosed for your use.

On page 1, delete paragraph 1 (lines 5-12) and replace with the following paragraph: --This application is a divisional of U.S. Application Serial No. 08/466,103, filed June 6, 1995, which application is a continuation-in-part of U.S. Application Serial No. 08/319,887, filed October 7, 1994, now abandoned, which application is a continuation in-part of U.S. Application Serial No. 08/261,857, filed June 17, 1994, now abandoned, all of which applications are incorporated herein by reference in their entirety.--

"EXPRESS MAIL" Mailing Label Number ELO10098256US

Date of Deposit January 5, 1999
I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Joan Gray
USA 6 Gray

In the Claims:

Cancel claims 1-17, 31 and 32.

24. (Amended) The receptor protein of claim [14]18, having an amino acid sequence substantially identical to the amino acid sequence shown in Fig. 6 (SEQ ID NO:6).

35. (Amended) The method of claim [25 or 26]33, wherein said cell is a mammalian cell which normally presents substantially no high-affinity melatonin receptor on its surface.


REMARKS

Upon entering of this amendment, claims 18-30 and 33-36 will be pending in this new divisional application, claims 1-17, 31 and 32 having been cancelled.

Claim 24 has been amended to depend from claim 18 and claim 35 has been amended to depend from claim 33. These amendments have been made to correct the claim dependencies of claims 24 and 35, which were incorrect due to typographical errors. No new matter has been added.

Respectfully submitted,

Date: Ju.S, 1999


Janis K. Fraser, Ph.D., J.D.

Reg. No. 34,819

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804

Telephone: 617/542-5070
Facsimile: 617/542-8906
348324.B11

**APPLICATION
FOR
UNITED STATES LETTERS PATENT**

TITLE: HIGH-AFFINITY MELATONIN RECEPTOR AND USES
THEREOF

APPLICANT: STEVEN M. REPPERT
TAKASHI EBISAWA

HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF

Cross-Reference to Related Applications

5 This application is a continuation-in-part of our earlier filed (pending) U.S. application Serial No. 08/319,887 filed October 7, 1994 which application is a continuation-in-part of our earlier filed (pending) U.S. application Serial No. 08/261,857 filed June 17, 1994 which
10 application is incorporated herein by reference in its entirety and to which application we claim priority under 35 USC §120.

Statement as to Federally Sponsored Research

15 This invention was made at least in part with funds from the Federal government, and the government therefore has rights in the invention.

Background of the Invention

20 The invention relates to nucleic acids and their encoded high-affinity melatonin receptor proteins.

25 The high-affinity melatonin receptor is a membrane protein that is coupled to guanine nucleotide binding proteins (G proteins). G proteins, in turn, communicate ligand-activated receptor signals to the appropriate intracellular effector system(s). The hormone, melatonin, inhibits adenylyl cyclase causing a decrease in intracellular cyclic AMP (cAMP) concentration.

 Melatonin, the principal hormone of the vertebrate pineal gland, elicits potent neurobiological effects. Melatonin influences circadian rhythm and mediates the

effects of photoperiod on reproductive function in seasonally breeding mammals. In humans, melatonin administration has been shown to alleviate the symptoms of jet lag after air travel across several time zones. The 5 hormone also has potent sedative effects in humans and may be a useful hypnotic agent.

Melatonin exerts its photoperiodic and circadian effects through pharmacologically specific, high-affinity receptors (Dubocovich, M.L. and Takahashi, J., P.N.A.S. USA 10 (1987) 84:3916-3920; Vanecek, J., J. Neurochem. (1988) 51:1436-1440; Reppert et al., (1988) supra). In seasonally breeding mammals, pineal melatonin secretion regulates seasonal responses to changes in day length (Bartness, T.J. and Goldman, B.D., Experientia (1989) 45:939-945; Karsch et 15 al., Recent Prog. Horm. Res. (1984) 40:185-232). The only site containing melatonin 1a receptors in all photoperiodic species examined to date (Weaver, et al., Suprachiasmatic nucleus: the mind's clock. Klein, D.C., Moore, R.Y, and Reppert, S.M., eds. New York: Oxford University Press; 20 (1991) pp. 289-308) is the pars tuberalis (PT), a portion of the pituitary gland. In contrast to other species, in humans melatonin 1a receptors are not consistently present in the PT.

High-affinity melatonin-1a (Mel-1a) receptors are 25 located in discrete regions of the vertebrate central nervous system of several mammalian species, including humans. Binding studies using the ligand 2-[¹²⁵I]-iodomelatonin (¹²⁵I-melatonin or [¹²⁵I]MEL) have identified high-affinity melatonin 1a receptors ($K_d < 2 \times 10^{-10}$ M) in sites 30 such as the suprachiasmatic nuclei (SCN), the site of a biological clock that regulates numerous circadian rhythms (Reppert et al., Science (1988) 242:78-81). To date, high-

affinity melatonin receptors have not been identified in central nervous system tissues other than brain.

Receptor affinity is sensitive to guanine nucleotides and activation of the receptors consistently

5 leads to the inhibition of adenylyl cyclase through a pertussis toxin-sensitive mechanism (Rivkees, S.A. et al., P.N.A.S. USA (1989) 86:3883-3886; Carlson, L.L. et al., Endocrinology (1989) 125:2670-2676; Morgan, P.J. et al., Neuroendocrinology (1989) 50:358-362; Morgan, P.J. et al.,

10 J. Neuroendocrinol. (1990) 2:773-776; Laitinen, J.T. and Saavedra, J.M., Endocrinology (1990) 126:2110-2115). High-affinity melatonin receptors thus appear to belong to the superfamily of G protein-coupled receptors.

Summary of the Invention

15 In general, the invention features substantially pure DNA (cDNA or genomic DNA) encoding a high-affinity melatonin 1a receptor in brain and melatonin 1b receptor in retina. The invention also features substantially pure high-affinity melatonin 1a and 1b receptor polypeptides. In preferred embodiments, the receptor includes an amino acid sequence substantially identical to the amino acid sequence shown in Fig. 1 (SEQ ID NO:2); Fig. 2 (SEQ ID NO:4); Fig. 3 (SEQ ID NO:14); Fig. 5 (SEQ ID NO:12) or comprising the amino acid sequence of Fig. 4 (SEQ ID NO:6) for melatonin-1a

25 receptors.

The invention also features a new class of melatonin receptor designated melatonin-1b (Mel-1b) distinguished by its tissue distribution and binding characteristics. In preferred embodiments, the Mel-1b receptor includes an amino acid sequence substantially identical to the amino acid sequence shown in Fig. 6 (SEQ ID NO:16).

The invention includes a polypeptide having an amino acid sequence which includes a domain capable of binding melatonin and bringing about a decrease in intracellular cAMP concentration, and which is at least 80% identical to
5 the amino acid sequence shown in Figs. 1 - 6. The invention also features a substantially pure polypeptide which is a fragment or analog of a high-affinity melatonin-1a or melatonin-1b receptor and which includes a domain capable of binding melatonin and bringing about a decrease in
10 intracellular cAMP concentration.

In various preferred embodiments, the receptor or receptor fragment is derived from a vertebrate animal, preferably, human, sheep, mouse, or *Xenopus laevis*.

By "high-affinity melatonin receptor polypeptide" is meant all or part of a vertebrate cell surface protein which specifically binds melatonin and signals the appropriate melatonin-mediated cascade of biological events (e.g., a decrease in intracellular cAMP) concentration. The polypeptide is characterized as having the ligand binding properties (including the agonist and antagonist binding properties) and tissue distribution described herein.
15
20

By a "polypeptide" is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation).

By "substantially pure" is meant that the high-affinity melatonin receptor polypeptide provided by the invention is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, high-affinity melatonin receptor polypeptide. A substantially pure high-affinity melatonin receptor polypeptide may be obtained, for example, by
25
30

extraction from a natural source; by expression of a recombinant nucleic acid encoding a high-affinity melatonin receptor polypeptide, or by chemically synthesizing the protein. Purity can be measured by any appropriate method,
5 e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

By a "substantially identical" amino acid sequence is meant an amino acid sequence which differs only by conservative amino acid substitutions, for example,

- 10 substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non-conservative amino acid substitutions, deletions, or insertions located at positions of the amino acid sequence which do not destroy the biological activity
15 of the receptor. Such equivalent receptors can be isolated by extraction from the tissues or cells of any animal which naturally produce such a receptor or which can be induced to do so, using the methods described below, or their equivalent; or can be isolated by chemical synthesis; or can
20 be isolated by standard techniques of recombinant DNA technology, e.g., by isolation of cDNA or genomic DNA encoding such a receptor.

By "derived from" is meant encoded by the genome of that organism and present on the surface of a subset of that
25 organism's cells.

In another related aspect, the invention features isolated DNA which encodes a high-affinity melatonin-1a or melatonin-1b receptor (or receptor fragment or analog thereof) described above. Preferably, the purified DNA is
30 cDNA; is cDNA which encodes a *Xenopus laevis* high-affinity melatonin receptor; is cDNA which encodes a sheep high-affinity melatonin-1a receptor; and is cDNA which encodes a

human high-affinity melatonin-1a; and is cDNA which encodes a human high-affinity melatonin-1b receptor.

By "isolated DNA" is meant a DNA that is not immediately contiguous with (i.e., covalently linked to) both of the coding sequences with which it is immediately contiguous (i.e., one at the 5' end and one at the 3' end) in the naturally-occurring genome of the organism from which the DNA of the invention is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

In other related aspects, the invention features vectors which contain such isolated DNA and which are preferably capable of directing expression of the protein encoded by the DNA in a vector-containing cell; and cells containing such vectors (preferably eukaryotic cells, e.g., CHO cells (ATCC; Cat. No. CCL 61 or COS-7 cells (ATCC; Cat. No. CRL 1651). Preferably, such cells are stably transfected with such isolated DNA.

By "transformed cell" is meant a cell into which (or into an ancestor of which) has been introduced, by means of genetic engineering, a DNA molecule encoding a high-affinity melatonin receptor (or a fragment or analog, thereof). Such a DNA molecule is "positioned for expression" meaning that the DNA molecule is positioned adjacent to a DNA sequence which directs transcription and translation of the sequence (i.e., facilitates the production of the high-affinity melatonin receptor protein, or fragment or analog, thereof).

By "specifically binds", as used herein, is meant an agent, such as melatonin, a melatonin analog or other chemical agent including polypeptides such as an antibody, which binds high-affinity melatonin receptor, receptor 5 polypeptide or a fragment or analog thereof, but which does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally includes a high-affinity melatonin receptor polypeptide. Preferably, the agent activates or inhibits the biological activity *in vivo* of the 10 protein to which it binds. By "biological activity" is meant the ability of the high-affinity melatonin receptor to bind melatonin and signal the appropriate cascade of biological events (as described herein).

In yet another aspect, the invention features a 15 method of screening candidate compounds for their ability to act as an agonist of a high-affinity melatonin-1a or melatonin-1b receptor ligand. The method involves:
a) contacting a candidate agonist compound with a recombinant high-affinity melatonin receptor (or melatonin-
20 binding fragment or analog); b) measuring binding of the ligand to the receptor, the receptor polypeptide or the receptor fragment or analog; and c) identifying agonist compounds as those which bind the recombinant receptor and trigger a decrease in intracellular cAMP concentration.

By an "agonist" is meant a molecule which mimics a particular activity, in this case, the ability of a high-affinity melatonin receptor ligand to bind a high-affinity melatonin receptor and to trigger the biological events resulting from such an interaction (e.g., decreased 25 intracellular cAMP concentration). An agonist may possess greater activity than the naturally-occurring high-affinity melatonin receptor ligand.

In yet another aspect, the invention features a method of screening a candidate compound for its ability to antagonize interaction between melatonin and a high-affinity melatonin receptor. The method involves: a) contacting a 5 candidate antagonist compound with a first compound which includes a recombinant high-affinity melatonin receptor (or melatonin-binding fragment or analog) on the one hand and with a second compound which includes melatonin on the other hand; b) determining whether the first and second compounds 10 bind; and c) identifying antagonistic compounds as those which interfere with the binding of the first compound to the second compound and which reduce melatonin-mediated decreases in intracellular cAMP concentration.

By an "antagonist" is meant a molecule which 15 inhibits a particular activity, in this case, the ability of melatonin to interact with a high-affinity melatonin receptor and to trigger the biological events resulting from such an interaction (e.g., decreased intracellular cAMP concentration.)

20 In preferred embodiments of both screening methods, the recombinant high-affinity melatonin receptor is stably expressed by a mammalian cell which normally presents substantially no high-affinity melatonin receptor on its surface (i.e., a cell which does not exhibit any significant 25 melatonin-mediated decrease in intracellular cAMP concentration); the mammalian cell is a CHO cell or a COS-7 cell; and the candidate antagonist or candidate agonist is a melatonin analog or other chemical agent including a polypeptide such as an antibody.

30 The receptor proteins of the invention are likely involved in the control of vertebrate circadian rhythm. Such proteins are therefore useful to develop therapeutics to treat such conditions as jet lag, facilitate

reentrainment of some endogenous melatonin rhythms, synchronize the disturbed sleep-wake cycle of blind people, alleviate sleep disorders in shift workers, facilitate the emergence of a diurnal sleep-wake pattern in neonates,

5 regulate ovarian cyclicity in human females, control the initiation and timing of puberty in humans, and alter the mating cycle in seasonally breeding animals, such as sheep. Preferred therapeutics include 1) agonists, e.g., melatonin analogs or other compounds which mimic the action of

10 melatonin upon interaction with the high affinity melatonin receptor; and 2) antagonists, e.g., melatonin analogs, antibodies, or other compounds, which block melatonin or high-affinity melatonin receptor function by interfering with the melatonin:receptor interaction.

15 A "transgenic animal" as used herein denotes an animal (such as a non-human mammal) bearing in some or all of its nucleated cells one or more genes derived from a different species (exogenous); if the cells bearing the exogenous gene include cells of the animal's germline, the

20 gene may be transmissible to the animal's offspring. As used herein, genes derived from a different species of animal are exogenous genes. Preferably the exogenous genes include nucleotide sequences which effect expression of the gene in its endogenous tissue distribution.

25 Because the receptor component may now be produced by recombinant techniques and because candidate agonists and antagonists may be screened using transformed, cultured cells, the instant invention provides a simple and rapid approach to the identification of useful therapeutics. Such

30 an approach was previously difficult because of the localization of the receptor to a few discrete regions in the central nervous system of most mammals. Isolation of the high-affinity melatonin receptor gene (as cDNA) allows

its expression in a cell type which does not normally bear high-affinity melatonin receptors on its surface, providing a system for assaying a melatonin:receptor interaction.

Other features and advantages of the invention will
5 be apparent from the following description of the preferred
embodiments thereof, and from the claims.

Detailed Description

The drawings will first briefly be described.

Drawings

10 Fig. 1 is the complete nucleotide and amino acid sequences (SEQ ID NO:1 and SEQ ID NO:2, respectively) of the *Xenopus laevis* high-affinity melatonin receptor gene coding region cDNA. The deduced amino acid sequence of the receptor is provided below the nucleotide sequence (reading frame b) and contains 420 amino acids. The deduced amino acid sequence begins at nucleotides 32, 33, 34 (ATG = Met) and ends with nucleotides 1292, 1293, 1294 (TGA = stop).

15 Fig. 2 is the complete nucleotide and amino acid sequences (SEQ ID NO:3 and SEQ ID NO:4, respectively) of the sheep high-affinity melatonin-1a receptor gene coding region which is a genetic fusion of genomic DNA from the 5' region and cDNA from the 3' region as described below. The deduced amino acid sequence of the receptor is provided below the nucleotide sequence and contains (reading frame a) 366 amino acids. The deduced amino acid sequence begins at nucleotides 49, 50, 51 (ATG = Met) and ends at nucleotides 1147, 1148, 1149 (TAA = stop).

20 Fig. 3 is the complete nucleotide and amino acid sequences (SEQ ID NO:13 and SEQ ID NO:14, respectively) of the mouse high-affinity melatonin-1a receptor gene coding region. The deduced amino acid sequence of the receptor is

provided below the nucleotide sequence and contains (reading frame a) 353 amino acids. The deduced amino acid sequence begins at nucleotides 1-3 (ATG = Met) and ends at nucleotides 1060-1062 (TAA = stop).

5 Fig. 4 is the nucleotide and deduced amino acid sequences (SEQ ID NO:5 and SEQ ID NO:6, respectively) of a fragment of the human high-affinity melatonin receptor gene coding region genomic DNA. The coding sequence corresponds to the region downstream (3') of the first intron. From the
10 sequenced portion of the receptor DNA, the deduced amino acid sequence is provided below the nucleotide sequence (reading frame a) and contains 288 amino acids. The coding region of the partial sequence begins at nucleotides 1, 2, 3 (GGA = Gly) and ends at nucleotides 865, 866, 867
15 (TAA = stop).

Fig. 5 is the complete nucleotide and amino acid sequences (SEQ ID NO:11 and SEQ ID NO:12, respectively) of the human high-affinity melatonin receptor cDNA. The deduced amino acid sequence of the receptor is provided
20 below the nucleotide sequence (reading frame c) beginning at nucleotides 33-35 (ATG = Met) and contains 350 amino acids ending at nucleotides 1083-1085 (TAA = stop).

Fig. 6 is the complete nucleotide and amino acid sequences (SEQ ID NO:15 and SEQ ID NO:16, respectively) of the human high-affinity melatonin-1b receptor cDNA. The deduced amino acid sequence of the receptor is provided
25 below the nucleotide sequence (reading frame a) beginning at nucleotides 13-15 (ATG = Met), ending at nucleotides 1096-1098 (TAA = stop) and contains amino 362 acids.

30 Fig. 7 shows the alignment of the deduced amino acid sequences (SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6, respectively) and the hydrophobic regions (boxes I-VII) of

the entire *Xenopus* and sheep, and partial human high-affinity melatonin receptors.

Fig. 8 shows the alignment of the deduced amino acid sequences (SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:12, respectively) and the hydrophobic regions (presumed transmembrane domains I-VII highlighted by solid bars) of the entire *Xenopus*, sheep, and human high affinity melatonin receptors. To indicate homology, gaps (represented by dots) have been introduced into the three sequences.

Fig. 9 is the proposed structure of the *Xenopus* high-affinity melatonin receptor in the cell membrane. The deduced amino acid sequence (SEQ ID NO:2) is depicted. Y, potential N-linked glycosylation site. Solid circles represent consensus sites for protein kinase C phosphorylation.

Figs. 10a and 10b show ^{125}I -melatonin binding assay results from COS-7 cells containing *Xenopus* melatonin receptor cDNA. Fig. 11a shows a saturation curve. Nonspecific binding was determined using 10 μM melatonin. Fig. 11b shows a single representative Scatchard plot of the saturation data for determining the relative ^{125}I -melatonin binding constants for the transfected high-affinity melatonin receptor gene from *Xenopus*.

Fig. 11 shows competition by various ligands for ^{125}I -melatonin binding in COS-7 cells transfected with the melatonin receptor cDNA from *Xenopus*. Cells were incubated with 100 pM ^{125}I -melatonin and various concentrations of 2-iodomelatonin (I-MEL), melatonin (MEL), 6-chloromelatonin (6Cl-MEL), 6-hydroxymelatonin (6OH-MEL), N-acetyl-5-hydroxytryptamine (NAS), or 5-hydroxytryptamine (5HT). Nonspecific binding was determined in the presence of 10 μM melatonin. K_i values are: I-MEL, $1.1 \times 10^{-10} \text{ M}$; MEL,

1.3 x 10⁻⁹ M; 6Cl-MEL, 3.0 x 10⁻⁹ M; 6OH-MEL, 2.0 x 10⁻⁸ M; NAS, 2.0 x 10⁻⁶ M; 5HT, >1.0 x 10⁻⁴ M. The data are representative of three experiments.

Fig. 12 shows melatonin inhibition of forskolin-stimulated cAMP accumulation in CHO cells stably transfected with the melatonin receptor cDNA from *Xenopus*. The 100% value is the mean cAMP value induced with 10 μ M forskolin. The data are representative of three experiments.

Fig. 13 is a Northern blot of melatonin receptor transcripts in *Xenopus* derived melanophores. Locations of RNA size markers (Life Technologies, Bethesda, MD) are indicated. The blot was exposed to X-ray film overnight.

Fig. 14 shows ¹²⁵I-melatonin binding assay results from COS-7 cells containing sheep melatonin receptor cDNA. Fig. 14a shows a saturation curve. Nonspecific binding was determined using 10 μ M melatonin. Fig. 14a (inset) shows a Scatchard plot of the saturation data for determining the relative ¹²⁵I-melatonin binding constants for the transfected high-affinity melatonin receptor gene from sheep. The K_d value for the sheep melatonin high-affinity receptor is 3.6 x 10⁻¹¹ M and the B_{max} value is 104 fmol/mg protein. Nonspecific binding was determined using 10 μ M melatonin. Data shown are representative of three experiments.

Fig. 14b is a plot of competition by various ligands for ¹²⁵I-Mel binding in COS-7 cells transfected with the sheep melatonin receptor cDNA (SEQ ID NO:3). Cells were incubated with 100 pM ¹²⁵I-Mel and various concentrations of 2-iodomelatonin (I-Mel), melatonin (Mel), 6-chloromelatonin (6Cl-Mel), 6-hydroxymelatonin (6OH-Mel), N-acetyl-5-hydroxytryptamine (NAS), or 5-hydroxytryptamine (5-HT). Nonspecific binding was determined in the presence of 10 μ M melatonin. K_i values for the sheep receptor are:

I-Mel, 3.7×10^{-11} M; Mel, 2.4×10^{-10} M; 6Cl-Mel, 2.5×10^{-10} M; 6OH-Mel, 3.0×10^{-9} M; NAS, 1.4×10^{-7} M; 5HT, $>1.0 \times 10^{-4}$ M.

Inhibition curves were generated by LIGAND (Munson, P.L. and Rodbard, *D. Anal. Biochem.* (1980) 107:220-239) using a one-

5 site model. The data shown are representative of at least three experiments. 2-Iodomelatonin is available from Research Biochemicals Inc., Natick, MA; 6-chloromelatonin is available from Ely Lilly, Indianapolis, IN; all other drugs used herein are available from Sigma, St. Louis, MO.

10 Fig. 15 shows ^{125}I -melatonin binding assay results from COS-7 cells containing the complete human melatonin 1a receptor cDNA (SEQ ID NO:11). Fig. 15a shows a saturation

15 curve. Fig. 15a (inset) shows Scatchard plot of the saturation data for determining the relative ^{125}I -melatonin binding constants for the transfected high-affinity

melatonin receptor gene from human. The K_d value for the human high-affinity melatonin 1a receptor is 2.6×10^{-11} M and the B_{max} value is 220 fmol/mg protein. Nonspecific binding was determined using 10 μM melatonin. Data shown

20 are representative of three experiments. Fig. 16b is a plot of competition by various ligands for ^{125}I -Mel binding in COS-7 cells transfected with the human melatonin receptor cDNA (SEQ ID NO:11). Cells were incubated with 100 pM ^{125}I -Mel and various concentrations of 2-iodomelatonin

25 (I-Mel), melatonin (Mel), 6-chloromelatonin (6Cl-Mel), 6-hydroxymelatonin (6OH-Mel), N-acetyl-5-hydroxytryptamine (NAS), or 5-hydroxytryptamine (5-HT). Nonspecific binding was determined in the presence of 10 μM melatonin. K_i values for the human receptor are: I-Mel, 1.8×10^{-11} M; Mel,

30 2.3×10^{-10} M; 6Cl-Mel, 2.0×10^{-9} M; 6OH-Mel, 2.0×10^{-9} M; NAS, 1.7×10^{-7} M; 5HT, $>1.0 \times 10^{-4}$ M. Inhibition curves were generated by LIGAND (Munson and Rodbard (1980), *supra*) using

a one-site model. The data shown are representative of at least three experiments.

Fig. 16 is the results of studies showing that recombinant mammalian melatonin receptor couples to G_i.

- 5 Fig. 16a shows melatonin inhibition of forskolin-stimulated cAMP accumulation in NIH 3T3 cells stably transfected with the sheep melatonin receptor cDNA (SEQ ID NO:3). The 100% value is the mean cAMP value induced with 10 μM forskolin. The data shown are representative of four experiments. Fig. 10 16b shows that pertussis toxin blocks the ability of melatonin to inhibit forskolin-stimulated cAMP accumulation in NIH 3T3 cells stably transfected with the sheep melatonin receptor cDNA (SEQ ID NO:3). Cells were preincubated with either vehicle or pertussis toxin for 18 hours (PTX: 15 100 ng/ml; pertussis toxin was purchased from List, Campbell, CA). C, Basal levels; F, 10 μM forskolin alone; FM, 10 μM forskolin plus 1 μM melatonin. Data are the mean plus standard deviation for 3 plates for each treatment. The data shown are representative of three experiments.

- 20 Fig. 17 shows a coronal section through the base of the sheep brain and pituitary. Fig. 17a is a histographic staining of the tissue section showing the pars tuberalis (PT) and the pars distalis (PD). Fig. 17b is a film autoradiographic image produced from a section to which 25 [¹²⁵I]MEL binding is observed in the PT. Fig. 17c is a film autoradiographic image produced from an *in situ* hybridization of a tissue section using a sheep high-affinity melatonin receptor riboprobe derived from the cloned receptor sequence. The hybridization pattern shows 30 that mRNA which hybridizes to the sheep high-affinity melatonin receptor riboprobe exhibits the same pattern of expression as the endogenous receptor protein.

Fig. 18 is a diagram of the structure of the human Mel-1b receptor protein. Fig. 18a is the predicted membrane topology of the human Mel-1b receptor protein. Y, Potential N-linked glycosylation site. Amino acids that are shaded are identical between human Mel-1b and the human Mel-1a melatonin receptors. Fig. 18b is a comparison of the deduced amino acid sequence of human Mel-1b and the human Mel-1a melatonin receptor (GenBank accession no. U14109) and the Xenopus melatonin receptor (U09561). To maximize homologies, gaps (dots) have been introduced into the three sequences. The seven presumed transmembrane domains (I-VII) are overlined. Consensus sites for N-linked glycosylation are underlined. The human melatonin 1b receptor sequence has been deposited in GenBank under accession number U25341.

Fig. 19 is a plot of human Mel-1b receptor expression in COS-1 cells assayed by ^{125}I -Mel binding. o, total binding; •, specific binding; ▲, nonspecific binding (determined in the presence of 10 μM melatonin). Inset: Scatchard plot of saturation data. The K_d value depicted is $1.5 \times 10^{-10} \text{ M}$. The B_{\max} value is 2.62 pmol/mg membrane protein. Data shown are representative of five experiments.

Fig. 20 is a graphical representation of competition by various ligands for ^{125}I -Mel binding in COS-1 cells transfected with either human Mel-1b or human Mel-1a melatonin receptor cDNA. Cells were incubated with 200 pM (Mel-1b receptor) or 100 pM ^{125}I -Mel (Mel-1a receptor) and various concentrations of 2-iodomelatonin (I-Mel), melatonin (Mel), 6-chloromelatonin (6Cl-Mel), or N-acetyl-5--hydroxytryptamine (NAS). Nonspecific binding was determined in the presence of 10 μM melatonin. The data shown are mean values of three to five experiments for each drug. K_i values are listed in Table 1.

Fig. 21 is a graphical representation of melatonin inhibition of forskolin-stimulated cAMP accumulation in NIH 3T3 cells stably transfected with human Mel-1b receptor. The 100% value is the mean cAMP value induced with 10 μ M forskolin. The data shown are mean values of two experiments.

Fig. 22 is a comparative RT-PCR analysis of Mel-1b and Mel-1a receptor gene expression in six human tissues. Brain refers to analysis of whole brain. H3.3 is histone

10 H3.3.

Fig. 23 is a diagram showing the chromosomal location of the Mel-1b receptor gene. The idiogram of human chromosome 11 illustrates the chromosomal content of the somatic cell hybrids used to localize the Mel-1b melatonin receptor gene (*MTNR1 B*), to 11q21-22.

There now follows a description of the cloning and characterization of the high-affinity melatonin receptor cDNA from *Xenopus laevis*, the high-affinity melatonin 1a receptor from sheep, mouse, and human as well as the high affinity melatonin 1b receptor from human useful in the instant invention. Transformed cells containing and expressing the cDNA of the invention are also described. This example is provided for the purpose of illustrating the invention, and should not be construed as limiting.

25 Molecular Cloning of a High-Affinity Melatonin Receptor from Xenopus laevis.

Melatonin receptors are present in the dermal melanophores of amphibians (Bagnara, J.T. and Hadley, M.E., *Am. Zoologist* (1970) 10:201-216). The action of melatonin, 30 mediated through the high-affinity melatonin receptor coupled to G_i protein (Abe, K. et al., *Endocrinology* (1969)

85:674-682; White, B.H. et al., J. Comp. Physiol. (1987) B 157:153-159) results in melanin aggregation in the dermal melanophores. mRNA from *Xenopus* dermal melanophores was used to clone the *Xenopus* high-affinity melatonin receptor 5 cDNA (Ebisawa, T. et al., PNAS USA (1994) 91:6133-6137). Either primary cells or immortalized cells may be used for the purpose of mRNA isolation. Cloning of the *Xenopus* high-affinity melatonin receptor cDNA was accomplished as a useful initial step toward cloning of the high-affinity 10 melatonin receptors of higher eukaryotes.

The immortalized cell line used for mRNA isolation was found to express a high level of ^{125}I -melatonin binding (≥ 100 fmol/mg total cell protein using 50 pM ^{125}I -melatonin). The cells were cultured by the method of Daniolos et al. 15 (Pigment Cell Res. (1990) 3:38-43). Using standard techniques, total cellular RNA was isolated from melanophores by extraction with guanidinium thiocyanate followed by centrifugal separation in a cesium chloride density gradient (Sambrook et al., Molecular Cloning: A 20 Laboratory Manual (Cold Spring Harbour Lab. Press, Plainview, NY), (1989) 2nd Ed.). Removal of melanosomes prior to separation on the cesium chloride density gradient was performed as described by Karne et al. (J. Biol. Chem. (1993) 268:19126-19133). Poly(A)⁺ RNA was isolated using 25 established methods as described in Rivkees et al. (P.N.A.S. USA (1989) 84:3916-3920).

The poly(A)⁺ RNA from *Xenopus* dermal melanophores was used as a template for the construction of a random primed cDNA library (cDNA Synthesis Kit, Pharmacia Biotech 30 Inc., Piscataway, NJ). Cohesive ends were produced on the double stranded cDNA by ligating with *Bst*X1 and *Eco*R1 adaptors (InVitrogen, San Diego, CA). The cDNA was size-

fractionated on an agarose gel, and cDNA having a length equal to or greater than 2 kilobase pairs (kb) was recovered by electroelution. The size-selected cDNA was ligated into the expression vector pcDNAI (InVitrogen, San Diego, CA) and 5 introduced into *E. coli* strain MC1061/P3 by electroporation.

A total of 4×10^5 recombinants were obtained from 5 μg of poly(A)⁺ RNA and divided into 54 pools, each containing approximately 7400 clones. Plasmid DNA was prepared from each pool by the alkaline lysis method and 10 transfected into COS-7 cells by the DEAE-dextran method (Cullen, B.R., Methods Enzymol. (1987) 152:684-704). COS-7 cells were grown as monolayers in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, penicillin (50 U/ml), and streptomycin (50 $\mu\text{g}/\text{ml}$), in 5% CO₂, 15 at 37°C. Three days after transfection, cells were incubated with 90 pM ¹²⁵I-melatonin Tris-HCl pH 7.4, containing 100 mM NaCl, 5 mM KCl, 2 mM CaCl₂, and 5% Nu-Serum I (Collaborative Biomedical Products, Bedford, MA), for 2 hr at room temperature. Cells were washed, air dried, 20 and exposed to X-ray film for 14 days. A pool of clones which showed positive signals was subdivided, and the transfection procedure was repeated. This subdividing process was continued until a single clone was identified that conferred specific ¹²⁵I-melatonin binding to COS-7 25 cells.

This clone, which contained a 2.2 kb cDNA, insert was isolated and both strands of the coding region were sequenced (SEQ ID NO:1). Nucleotide sequences were analyzed by the dideoxynucleotide chain termination method of Sanger, 30 F. et al. (P.N.A.S. USA (1977) 74:5463-5467) using Sequenase® (United States Biochemical, Cleveland, OH). The sequencing template was double-stranded plasmid DNA.

Sequencing primers were synthetic oligonucleotides that were either vector specific or derived from sequence information.

The isolated *Xenopus* cDNA encodes a protein of 420 amino acids (Fig. 1) (SEQ ID NO:2) with an estimated molecular mass of 47,424. The flanking DNA sequence of the first two methionine codons in this reading frame both displayed a Kozak consensus sequence for the initiation of translation (Kozak, M., Nucleic Acids Res. (1987) 15:8125-8148). Hydropathy analysis (Kyte, J. and Doolittle, R.F., J. Mol. Biol. (1982) 157:195-232) of the predicted amino acid sequence revealed the presence of seven hydrophobic domains (see Figs. 4 and 5) which likely represent the transmembrane regions of a G protein-coupled receptor. The amino terminus contains a consensus site for N-linked glycosylation, a feature typical of most G protein-coupled receptors (Pearson, W.R., Methods Enzymol. (1990) 183:63-98). The melatonin receptor protein is not similar in identity to any one particular group of G protein-coupled receptors, but is similar to a wide range of receptors; the highest amino acid sequence identity scores were approximately 25% for both the mu opioid and type 2 somatostatin receptors. Using a G protein-coupled receptor database (Kornfeld, R. and Kornfeld, D., Ann. Rev. Biochem. (1985) 54:631-664), the melatonin receptor appears to form a group that is distinct from other known biogenic amine and peptide receptors. No sequence homology was identified between the melatonin receptor and the metabotropic glutamate or parathyroid hormone/calcitonin/secretin receptor gene families (Masu et al., Nature (1991) 349:760-765; Juppner, et al., Science (1991) 254:1024-1026; Lin et al., Science (1991) 254:1022-1024).

The melatonin receptor has some general structural features in common with amine and peptide receptors. For

example, it contains a single cysteine residue in each of the first two extracellular loops that, based on mutagenesis studies of opsin and amine receptors (Dixon et al., EMBO J. (1987) 6:3269-3275; Karnic et al., P.N.A.S. USA (1988) 85:8459-8463), are believed to form a disulfide bridge which stabilizes receptor structure. Furthermore, proline residues are present in transmembrane domains IV, V and VI (Fig. 7 and Fig. 8) which have been suggested to introduce kinks in the alpha-helices that may be important in forming the ligand binding pocket (Findlay, J. and Eliopoulos, E., Trends Pharmacol. Sci. (1990) 11:492-499; Hibert, M.F. et al., Mol. Pharmacol. (1991) 40:8-15). The proline in the NPXXY (SEQ ID NO:7) motif that is found in transmembrane domain 7 of virtually all other G protein-coupled receptors is replaced by an alanine in the melatonin receptor. The carboxyl tail of the melatonin receptor is 119 amino acid residues long and contains several consensus sites for protein kinase C phosphorylation which may be involved in receptor regulation (Sibley et al., Cell (1987) 48:913-922).

20 Binding Studies of the Recombinant *Xenopus* High-Affinity Melatonin Receptor.

To establish the binding characteristics of the encoded *Xenopus* receptor (SEQ ID NO:2), the cDNA in pCDNAI was transiently expressed in COS-7 cells. Three days after transfection, medium was removed, the culture dishes were washed with PBS, and the cells were harvested. The cells were then pelleted (2500 rpm; 10 min, 4°C) and stored at -80°C. Whole cell binding studies were performed by thawing the cells and resuspending them in binding buffer (50 mM Tris-HCl, pH 7.4, with 5 mM MgCl₂) at a concentration of 456 µg protein/ml. The cell suspension was incubated with

¹²⁵I-melatonin (90 pm) in a total reaction volume of 0.2 ml binding buffer in the presence or absence of a melatonin agonist or antagonist; the suspension was incubated in a shaker bath for 1.5 hr at 25°C. Protein determinations were performed using the Pierce BCA Protein Assay (The Pierce Chemical Co., Rockford, IL). Binding data were analyzed by computer using the LIGAND Program of Munson and Rodbard ((1980) *supra*). The results are shown in Figs. 8 and 9.

To further establish the binding characteristics of the encoded *Xenopus* receptor (SEQ ID NO:2), the cDNA in pcDNAI was transiently expressed in COS-7 cells. Three days after transfection, saturation studies were performed using increasing concentrations of ¹²⁵I-melatonin (5 to 1280 pM) (Fig. 10a). Scatchard analysis (Fig. 10b) revealed that transfected COS-7 cells bound ¹²⁵I-melatonin with high affinity ($K_d = 63 \pm 3 \times 10^{-12}$; n = 3 experiments). The B_{max} value using the whole cell binding assay was 67 ± 7 fmol/mg of protein. No specific binding of ¹²⁵I-melatonin was found in mock-transfected COS-7 cells.

The pharmacological characteristics of specific ¹²⁵I-melatonin binding in acutely transfected COS-7 cells was next examined (Fig. 11). The order of inhibition of specific ¹²⁵I-melatonin binding of *Xenopus* recombinant melatonin receptor by six ligands was characteristic of a high-affinity melatonin receptor (Dubocovich, M.L. and Takahasi, J. (1987) *supra*; Rivkees et al. (1989) *supra*), with relative binding affinities having the order: 2-iodomelatonin > melatonin > 6-chloromelatonin > 6-hydroxymelatonin > n-acetyl-5-hydroxytryptamine > 5-hydroxytryptamine. Thus, the isolated *Xenopus laevis* cDNA of the instant invention encodes a protein with the affinity

and pharmacological properties expected of a high-affinity melatonin receptor.

The endogenous high-affinity melatonin receptor in *Xenopus* dermal melanophores is coupled to inhibition of adenylyl cyclase (Abe, K. et al. (1969) supra; White, B.H. et al. (1987) supra). To determine whether the receptor encoded by the recombinant cDNA (SEQ ID NO:1) of *Xenopus* was coupled to the adenylyl cyclase regulatory system, a clonal line of CHO (ATCC; Cat. No. CCL 61 cells) was stably transfected with the recombinant receptor cDNA and the melatonin-induced inhibition of forskolin-stimulated cAMP accumulation was determined.

Transformed CHO cells were plated on 35 mm culture dishes. After 48 hours, the cells were washed twice with Ham's F-12 (Life Technologies, Bethesda, MD). Cells were then incubated in the presence or absence of melatonin analogs (diluted in F-12) for 10 min at 37°C. Following treatment, the medium was aspirated and 1 ml of 50 mM acetic acid was added to the culture dish. The cells were collected, transferred to an Eppendorf tube, boiled for 5 min, and centrifuged (13,750 rpm for 15 min). The supernatant was collected and assayed for cAMP. All determinations were performed in triplicate. Cyclic AMP levels were determined in duplicate by radioimmunoassay (New England Nuclear, Boston, MA).

Induction of cAMP concentration increase by 10 μ M forskolin was inhibited by melatonin in a dose dependent manner (Fig. 12); the maximal inhibition of the mean forskolin-stimulated cAMP concentration was 68% at 1 \times 10⁻⁸ M melatonin. An IC₅₀ value of approximately 8 \times 10⁻¹⁰ M was determined by manual curve fitting of the data in Fig. 12. This value was very similar to the computer-

generated K_i value (1.3×10^{-9} M) determined for melatonin inhibition of specific ^{125}I -melatonin binding shown in Fig. 11. Melatonin, alone, (1×10^{-6} M) was found not to alter basal cAMP levels in stably transfected CHO cells. Further, 5 melatonin (1×10^{-6} M) did not inhibit the forskolin-stimulated increase in cAMP levels in CHO cells stably transfected with vector lacking the *Xenopus* cDNA. Thus, the recombinant melatonin receptor is negatively coupled to the cAMP regulatory system.

10 Expression of *Xenopus* Melatonin Receptor Transcripts.

Northern blot analysis (see below) of *Xenopus* dermal melanophores revealed at least 3 hybridizing transcripts between 2.4 and 4.4 kb under conditions of high stringency (see below) (Fig. 13). The presence of multiple 15 hybridizing bands may represent posttranscriptional modifications of the same gene, or the presence of transcripts from different, but structurally similar genes.

Northern analysis was performed using standard techniques (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989)). Poly(A)⁺ RNA was subjected to electrophoresis through a 1% agarose-formaldehyde gel, blotted onto GeneScreen (New England Nuclear, Boston, MA), and hybridized with a fragment of the coding region of the receptor cDNA labeled with 25 [α - ^{32}P]dCTP (2000 Ci/mmol) by the method of random priming (Promega, Madison, WI). Hybridizing conditions were 50% formamide, 1 M sodium chloride, 1% SDS, 10% dextran sulfate, and 100 $\mu\text{g}/\text{ml}$ denatured salmon sperm DNA, at 42°C overnight. The final washing of the blot was in 0.2X SSC/0.1% SDS at 30 65°C for 40 min. Blots were exposed at -80°C to X-ray film with an intensifying screen.

Isolation of Sheep High-Affinity Melatonin Receptor

To clone the high-affinity melatonin receptor from sheep using standard methods, fully degenerate primers were designed based on, for example, the peptide sequences 5' 5 AIAINRY (SEQ ID NO:8) (residues 125-131) and 3' FAVCWAPL (SEQ ID NO:9) (residues 252-259) of the *Xenopus* sequence (SEQ ID NO:1) (Fig 1). Using these populations of degenerate primers, RT PCR of sheep pars tuberalis mRNA amplified an approximately 400 bp cDNA fragment that was 65% 10 identical at the amino acid level with the corresponding region of the *Xenopus* melatonin receptor.

To isolate a longer cDNA sequence, this fragment was labeled (e.g., with [³²P]dCTP by random priming) producing a probe, and hybridization (under high stringency conditions) 15 was carried out on a sheep pars tuberalis cDNA library constructed in the ZAP II vector (Stratagene, La Jolla, CA) using standard hybridization techniques (see e.g., Ausubel et al., Current Protocols in Molecular Biology, supra). From 1 x 10⁶ recombinants screened, two hybridizing clones 20 were isolated and plaque purified using standard techniques. Both clones contained the entire 3' coding region, downstream from the predicted site of the third transmembrane domain. One clone extended 5' into the amino terminus region, upstream from the first transmembrane 25 domain, but did not contain the entire 5' end of the coding region. A 160 bp fragment of the 5' end of this cDNA clone was labelled (e.g., radiolabelled) by standard techniques (see e.g., Ausubel et al., supra) and used to probe (e.g., by the standard techniques described, supra) a sheep genomic 30 library (in EMBL-3, catalog number UL 1001d, Clontech, Palo Alto, CA). One clone was isolated and found to contain the remaining 5' sequence of the coding region using standard

sequencing techniques. A 150 bp fragment of this genomic clone, containing a methionine with a consensus sequence for the initiation of translation was isolated and ligated using standard techniques (see e.g., Sambrook (1989), supra) into 5 a vector (e.g., pcDNAI, InVitrogen, San Diego, CA) in frame with the corresponding downstream coding region of the cDNA. The ligated construct encodes a protein of 366 amino acids (SEQ ID NO:4) which binds [¹²⁵I]MEL with high affinity.

Binding Studies of the Recombinant Sheep High-Affinity
10 Melatonin Receptor

The sheep high-affinity melatonin 1a receptor (SEQ ID NO:3) DNA cloned into pcDNAI was transiently expressed in COS-7 cells. For ligand binding studies, the sheep receptor cDNA (SEQ ID NO:3) in pcDNAI was introduced into COS-7 cells 15 using the DEAE-dextran method (Cullen, B.R. Methods Enzymol. (1987) 152:684-704). Approximately two to three days after transfection, cell culture medium was removed, the cultures dishes were washed with PBS, and the cells were harvested. The cells were then pelleted (2500 rpm; 10 min, 4°C) and 20 stored at -80°C. Whole cell binding studies were performed by thawing the cells and resuspending them in binding buffer (50 mM Tris-HCl, pH 7.4, with 5 mM MgCl₂) at a concentration of 200-500 µg protein/ml. The cell suspension was incubated with ¹²⁵I-Mel with or without drugs in a total reaction 25 volume of 0.2 ml binding buffer; the suspension was incubated in a shaker bath for 1.5 hr at 25°C. All determinations were done in either duplicate or triplicate. Protein measurements were performed using the Pierce BCA Protein Assay. Binding data were analyzed by computer using the 30 LIGAND Program of Munson and Rodbard (1980).

Scatchard analysis (performed as described above for the *Xenopus* clone) revealed that COS-7 cells transfected with the sheep Mel-1a receptor clone bound ^{125}I -melatonin with high affinity ($K_d = 3.6 \pm 0.1 \times 10^{-11} \text{ M}$; mean \pm SE, $n = 3$ experiments). The B_{\max} value for the sheep receptor clone using the whole cell binding assay was greater than $112 \pm 5 \text{ fmol/mg}$ of protein (Fig. 14a). No specific binding of ^{125}I -melatonin was found in mock-transfected COS-7 cells.

The sheep Mel-1a receptor pharmacologic profile of relative binding affinities of melatonin derivatives was shown to be similar to *Xenopus* using the same assay techniques as described for *Xenopus*. Competitive binding of six ligands to sheep melatonin receptor expressed by acutely transfected COS-7 cells showed that the rank order of inhibition of specific ^{125}I -Mel binding by the six ligands was 2-iodomelatonin > melatonin = 6-chloromelatonin > 6-hydroxymelatonin > N-acetyl-5-hydroxytryptamine > 5-hydroxytryptamine (Fig. 14b).

The receptor encoded by the recombinant sheep melatonin 1a receptor was tested to determine whether it is coupled to inhibitory G protein (G_i), as has been shown with the endogenous receptor of several mammals, including sheep (Carlson, et al., (1989) supra; Morgan et al., (1990) supra). Clonal NIH 3T3 cells stably transfected with the sheep receptor cDNA (SEQ ID NO:3) subcloned into pcDNA1 NEO (Invitrogen, San Diego, CA) and exhibiting high levels of melatonin receptor binding (>10 fmol/60 mm dish of cells using 100 pM ^{125}I -Mel) were used. Transformed NIH 3T3 cells were plated on 35 mm dishes. After forty-eight hours, the cells were washed twice with DMEM, and then incubated with or without drugs (diluted in DMEM) for 10 min at 37°C. At the end of treatment, the medium was aspirated and 1 ml of

50 mM acetic acid was added. The cells were collected, transferred to an Eppendorf tube, boiled for 5 min, and centrifuged (13,750 rpm for 15 min). The supernatant was collected and assayed for cAMP. All determinations were
5 done in triplicate. Cyclic AMP levels were determined in duplicate by radioimmunoassay by standard techniques.

Although melatonin did not alter basal cAMP levels in the stably transfected lines, it did cause a dose-dependent inhibition of the cAMP increase induced by 10 μ M
10 forskolin (Fig. 16a). The estimated IC₅₀ value for melatonin was 1×10^{-10} M, comparable to the K_i value for melatonin inhibition of specific ¹²⁵I-Mel binding (2.4×10^{-10} M; see Fig. 14b). Importantly, melatonin (1 μ M) did not inhibit
15 forskolin-stimulated cAMP accumulation in NIH 3T3 cells stably transfected with the vector (pcDNAI NEO) lacking the sheep Mel-1a receptor cDNA.

Pertussis toxin pretreatment (PTX; 100 ng/ml) of receptor-transfected NIH 3T3 cells for 18 hours completely abolished the ability of 1 μ M melatonin to inhibit the
20 forskolin-stimulated increase in cAMP (Fig. 16b). Thus, like the endogenous high-affinity melatonin receptor of vertebrates (Carlson et al., (1989) supra; Morgan et al., (1990) supra; White et al., (1987) supra), the recombinant sheep Mel-1a receptor inhibits adenylyl cyclase through a
25 pertussis-toxin sensitive mechanism.

Northern blot analysis of sheep PT revealed a major hybridizing transcript of greater than 9.5 kb and a minor transcript at 4.2 kb. No hybridizing signals were found in pars distalis (data not shown). Using antisense cRNA probes
30 prepared using sheep melatonin 1a receptor cDNA, *in situ* hybridization of endogenous mRNA revealed a strong hybridization signal that was visible in film

- autoradiographs of the sheep PT (Fig. 17); no signal was detected in pars distalis. The mRNA distribution in PT was identical to that found for the receptor protein using ^{125}I -Mel in vitro autoradiography. The SCN region of sheep was
- 5 not examined for melatonin receptor mRNA because high-affinity melatonin receptors have not been identified in sheep SCN using ^{125}I -Mel in in vitro autoradiography (Bittman, E.L. and Weaver, D.R., Biol. Reprod. (1990) 43:986-993).
- 10 Brain tissue of Siberian hamster and rat were examined to illustrate the distribution of melatonin receptor in brain of other species in which melatonin is known to have affects on reproductive and circadian rhythms (Bartness, T.J. et al., J. Pineal Res. (1993) 15:161-190;
- 15 Margraf, R.R. and Lynch, G.R., Am. J. Physiol. (1993) 264:R615-R621; and Cassone, V.M., Trends Neurosci. (1990) 13:457-464). The major sites of specific ^{125}I -Mel binding and receptor transcript hybridization in Siberian hamster brain are the PT, SCN and paraventricular nucleus of the
- 20 thalamus as examined in adjacent sections by in vitro autoradiography (data not shown; see also Weaver, D.R. et al., J. Neurosci. (1989) 9:2582-2588). Thus, in this species, the distribution of melatonin 1a receptor mRNA and protein are identical and restricted to just a few sites in
- 25 brain. The PT and SCN regions exhibited receptor transcript hybridization and ^{125}I -Mel binding in adult and developing rats (data not shown). The distribution of melatonin 1a receptor mRNA was coincident to that of ^{125}I -Mel binding throughout the SCN in both rat and hamster.
- 30 In all non-human mammals we have examined, including the sheep (Fig. 15), Siberian hamster, Syrian hamster, and rat, in situ hybridization studies have readily detected

mRNA for the high-affinity melatonin 1a receptor in PT. The PT currently appears to be an important site through which melatonin mediates photoperiodic effects on reproductive function. The PT is the only site containing melatonin 1a
5 receptors (as detected with ^{125}I -Mel *in vitro* autoradiography) in all seasonally breeding mammals examined to date (Weaver et al., (1991) *supra*). The mechanisms by which the PT processes the daily melatonin signal and communicates that information to influence hypothalamic
10 neurosecretion are unknown. High-affinity melatonin receptors have not been consistently detected in the human PT by ^{125}I -Mel *in vitro* autoradiography, suggesting that neuroendocrine responses to melatonin in humans may occur through fundamentally different mechanisms than those that
15 underlie the regulation of reproduction in seasonally breeding species (Weaver, D.R. et al., *J. Clin. Endocrinol. Metab.* (1993) 76:295-301).

Isolation of the Mouse High-Affinity Melatonin Receptor

Degenerate primers were designed using regions
20 conserved among other mammalian Mel-1a receptor cDNAs such as those from sheep (see Fig. 2). Polymerase chain reaction (PCR) of mouse genomic DNA yielded a 466 bp fragment that was 94% identical at the amino acid level to the rat and Djungarian hamster Mel-1a receptor cDNAs. *In situ*
25 hybridization of adult C57BL/6J mouse brain using the PCR-generated fragment produced a hybridization pattern consistent with that expected for the Mel-1a melatonin receptor. Hybridization signal was most intense in the hypophyseal pars tuberalis. Southern blot analysis of
30 genomic DNA indicated a single-copy gene. RNA was isolated from a murine cell line (RT2-2) which expresses the Mel-1a

receptor. Northern analysis of poly(A)⁺ RNA indicated a transcript length of approximately 1.9 kb. RT-PCR was used to generate the full length coding region (1059 bp) of the receptor, which showed 84% amino acid identity to the human
5 Mel-1a receptor. RNase protection analysis, 5' and 3' RACE cloning, and screening of a BALB/c mouse EMBL3 SP6/T7 genomic library revealed that the receptor gene consists of 2 exons divided by a large (>8 kb) intron. The 3' untranslated region is 444 bp long, and includes the
10 polyadenylation signal AUUAAA. RNase protection assays suggest that a major transcription start site is located approximately 100 bp upstream of the initiation codon. The nucleotide sequence and deduced amino acid sequence of the mouse Mel-1a receptor are shown in Fig. 3.

15 The recombinant mouse Mel-1a receptor expressed on COS-7 cells bound melatonin with high affinity comparable to the binding affinity of sheep and human Mel-1a receptors.

Isolation of a Fragment of the Human High-Affinity Mel-1a Receptor

20 To clone the human high-affinity melatonin receptor, the degenerate primers based on the peptide sequences 5' AIAINRY (SEQ ID NO:8) (residues 125-131 of the *Xenopus* deduced amino acid sequence (SEQ ID NO:2)) and 3' FAVCWAPL (SEQ ID NO:9) (residues 252-259 of the *Xenopus* deduced amino
25 acid sequence (SEQ ID NO:2)) were used as described above. Human genomic DNA was amplified by standard PCR techniques using the degenerate primers and an approximately 400 bp fragment was isolated and sequenced by standard techniques. The deduced amino acid sequence of the 400 bp fragment was
30 65% identical at the amino acid level with the corresponding portion of the *Xenopus* high-affinity melatonin receptor.

The 400 bp fragment was labelled (e.g., by random primer labelling; see e.g., Ausubel, *supra*) and used to screen a human genomic library (in vector EMBL-3, Clontech, Palo Alto, CA, catalog number HL1067J) under high stringency
5 conditions using standard hybridization techniques (see, e.g., Ausubel, *supra*). Several positively hybridizing clones were identified from 1×10^6 recombinant clones screened. The clones were plaque purified by standard techniques, digested with appropriate restriction enzymes
10 and subcloned in to a convenient vector for sequencing (e.g., pBluescript®, Stratagene, La Jolla, CA). The human insert DNA (SEQ ID NO:5) of one clone was sequenced using standard techniques. Using the sheep (SEQ ID NO:3) and *Xenopus* (SEQ ID NO:1) nucleotide and deduced amino acid
15 sequences (SEQ ID NO:4 and SEQ ID NO:2, respectively) for comparison (see Fig. 7 and Fig. 8), the human insert DNA was found to contain a portion of the coding region from the "GNXFVV (SEQ ID NO:10) motif" just downstream from the first transmembrane domain (see Figs. 7 and 8) and extends through
20 the 3' end of the coding region. The human DNA of the sequenced clone is approximately 82% identical to the sheep nucleotide sequence (SEQ IN NO:5) of the corresponding region. The sheep and human deduced amino acid sequences (SEQ IN NO:4 and SEQ IN NO:6, respectively) are
25 approximately 80% identical in the corresponding regions. Thus the human DNA fragment (SEQ IN NO:5) isolated by the above techniques encodes a protein with strong identity to the corresponding portion of high-affinity melatonin receptor in another mammal, sheep.
30 The human genomic DNA contains an intron (> 2.0 kb in length) upstream of the "GNXFVV motif" (SEQ IN NO:10). To obtain the 5' portion of the coding region of the human

receptor, the 160 bp fragment of the coding region of the sheep receptor immediately upstream from this GNXFVV motif was used to reprobe the human genomic library at low stringency (for exemplary low stringency hybridization
5 conditions see e.g., Ausubel et al. (1989), supra). One positively hybridizing clone was isolated and found by standard sequence analysis to contain the 5' end of the coding region. RT-PCR (see e.g., Reppert, et al., Mol.
Endocrinol. (1991) 5:1037-1048) of mRNA from human
10 hypothalamus using specific primers directed at the 5' and 3' ends of the putative coding region amplified the expected cDNA, containing the coding region of the human melatonin receptor. The cDNA was subcloned into pcDNAI for sequence analysis and transient expression of the receptor
15 polypeptide.

The sequencing results show that cDNAs cloned in the instant invention encode a high-affinity melatonin receptor from *Xenopus*, sheep, and human. Overall, the coding regions of the sheep receptor and complete human receptor are about
20 60% identical with that of the *Xenopus* melatonin receptor. Within the transmembrane domains, the identity is 77%. The most dissimilar regions between the mammalian and frog receptors was in the amino and carboxyl terminal regions. The amino terminus of the mammalian receptors contains two
25 consensus sites for N-linked glycosylation, compared to one site in the frog receptor. Furthermore, the carboxyl tail of the sheep and human receptors is 65 amino acid residues shorter than the *Xenopus* receptor tail. The complete human high-affinity melatonin receptor DNA shows strong identity
30 (approximately 82% at the nucleotide level and approximately 80% at the amino acid level) to the sheep high-affinity melatonin receptor with 87% amino acid identity when comparison is limited to the transmembrane domains. This

high structural homology suggests that the human and sheep clones are species homologs of the same receptor.

Binding Studies of the Recombinant Human High-Affinity Mel-1a Receptor

- 5 The complete human high-affinity melatonin 1a receptor (SEQ ID NO:11) DNA cloned into pcDNAI was transiently expressed in COS-7 cells and binding studies were performed as described for the sheep receptor, supra. Scatchard analysis (performed as described above for the
10 *Xenopus* and sheep clones) revealed that COS-7 cells transfected with the complete human receptor clone (containing DNA of SEQ ID NO:11) bound ^{125}I -melatonin with high affinity ($K_d = 2.6$ and $2.3 \times 10^{-11} \text{ M}$; $n = 2$ experiments). The B_{\max} value using the whole cell binding assay was 210 and
15 220 fmol/mg protein for the human receptor in two experiments (Fig. 15). No specific binding of ^{125}I -melatonin was found in mock-transfected COS-7 cells. For the human clone, the rank order of inhibition was identical to that for sheep, except that 6-chloromelatonin was 10-fold less
20 potent in inhibiting specific ^{125}I -Mel binding (K_i values listed in legend of Fig. 13b). Thus, the recombinant sheep and human receptors bind ^{125}I -Mel with high affinity and exhibit the appropriate pharmacological characteristics of a high-affinity melatonin receptor (Dubocovich and Takahashi,
25 (1987) supra; Morgan et al., (1989) J. Endocrinol. 1:1-4; Rivkees et al., PNAS USA (1989) 86:3883-3886; Vanecek, J., J. Neurochem. (1988) 51:1436-1440).

Isolation of a Human High-Affinity Mel-1b Receptor.

- To clone melatonin receptor subtypes, PCR was used
30 to amplify human genomic DNA with degenerate oligonucleotide

primers based on conserved amino acid residues in the third and sixth transmembrane domains of the *Xenopus* melatonin receptor and mammalian Mel-*la* melatonin receptors.

For PCR with degenerate primers, genomic DNA was subjected to 30 cycles of amplification with 200 nM (final concentration) each of two oligonucleotide primers. Each reaction cycle consisted of incubations at 94°C for 45 sec, 45°C for 2 min and 72°C for 2 min, with AmpiTaq DNA polymerase (Perkin-Elmer Cetus). The amplified DNA was separated on an agarose gel. DNA bands were subcloned into pCRTMII using a TA Cloning Kit (Invitrogen), and recombinant clones were sequenced. For PCR with specific primers, either genomic DNA or first-strand cDNA reverse transcribed from RNA was subjected to 25 to 35 cycles of amplification using incubations at 94°C for 45 sec, 60°C for 45 sec and 72°C for 2 or 3 min. The amplified DNA was separated on an agarose gel. DNA bands were subcloned into pcDNA3 (Invitrogen) for expression studies and sequence analysis, or subjected to Southern analysis for the comparative reverse transcription polymerase chain reaction (RT-PCR) assay (described herein below).

A human genomic library in EMBL-3 SP6/T7 (Clontech) was plated and transferred to Colony Plaque Screen filters (New England Nuclear). The filters were screened under conditions of either high or reduced stringency. High stringency consisted of overnight hybridization in 50% formamide, 1 M sodium chloride, 1% SDS, 10% dextran sulfate, 100 µg/ml denatured salmon sperm at 42°C, with filters being washed in 2x SSC, 1% SDS at 65°C for 1 hr. Reduced stringency consisted of the same hybridization solution at 42°C, except the formamide concentration was 25%; the filters were washed in 2x SSC, 1% SDS at 55°C for 1 hr.

Lambda phage that hybridized to the probe were plaque-purified.

A novel cDNA fragment (364 bp) was found by sequence analysis using standard techniques to be 60% identical at 5 the amino acid level with either the human Mel-1a receptor or the *Xenopus* melatonin receptor. This PCR-fragment was labeled by a standard random priming technique and used to probe a human genomic library at high stringency. From 1 X 10⁶ recombinants, seven positively hybridizing clones were 10 identified and plaque purified. A 6 kb *SacI*-fragment of one of the genomic clones which hybridized to the PCR-generated cDNA fragment was subcloned and partially sequenced. This fragment contained the 3' end of the putative coding region and extended 5' to the GN motif in the first cytoplasmic 15 loop, in which an apparent intron occurred; a consensus intron splice site occurs at an identical location in the human and sheep Mel-1a receptor genes (SEQ ID NO:11 and SEQ ID NO:3, respectively; Reppert, S.M., Weaver, D.R. & Ebisawa, T. (1994) *Neuron* 13: 1177-1185). To obtain the 5' 20 portion of the coding region, a 160 bp fragment encoding the first transmembrane domain of the sheep Mel1a-melatonin receptor was used to reprobe the seven positive genomic clones at reduced stringency (Reppert, S.M. et al. (1994), supra). A 2.3 kb *SacI*-fragment of one of the genomic clones 25 which hybridized to the sheep receptor fragmentd was subcloned and sequenced by standard techniques. This *SacI*-fragment contained the apparent 5' end of the coding region which includes an upstream, in-frame methionine with a consensus sequence for the initiation of translation 30 (Kozak, M. (1987) *Nucleic Acids Res.* 15: 8125-8148) and a consensus site for N-linked glycosylation. RT-PCR of RNA from human brain using specific primers directed at the 5'

and 3' ends of the putative coding region amplified the expected cDNA with the appropriate splicing predicted from genomic analysis, indicating that the putative receptor gene is transcribed. A PCR-generated construct of the coding 5 region of human Mel-1b receptor was subcloned into pcDNA3 for expression studies and sequence analysis. The deduced amino acid sequence of human Mel-1b receptor was identical with the corresponding sequence of the SacI-genomic fragments.

10 Human melatonin-1b receptor encodes a protein of 362 amino acids (SEQ ID NO:16) with a predicted molecular mass of 40,188, not including posttranslational modifications (Fig. 6). Human Mel-1b is a member of a newly described melatonin receptor group that is distinct from the other 15 receptor groups (e.g., biogenic amine, neuropeptide, and photopigment receptors) that comprise the prototypic G protein-coupled receptor family (Ebisawa, et al. (1994) Proc. Natl. Acad. Sci. USA 91, 6133-6137; Reppert, S.M. et al. (1994), supra). Unique features of this group include a 20 NRY motif just downstream from the third transmembrane domain (rather than DRY) and a NAXXY motif (SEQ ID NO:17) in transmembrane 7 (rather than NPXXY (SEQ ID NO:7)) (Fig. 18). In addition, the human Mel-1b receptor, the mammalian Mel-1a receptors, and the *Xenopus* melatonin receptor all have a 25 CYICHS motif (SEQ ID NO:18) immediately downstream from NRY in the third cytoplasmic loop which is a consensus site for cytochrome c family heme binding (Mathews, F.S. (1985) Prog. Biophys. Mol. Biol. 45: 1-56). Pair-wise comparisons of the human Mel-1b receptor, the human Mel-1a receptor and the 30 *Xenopus* melatonin receptor reveal approximately 60% amino acid identity for any pair of the three sequences (Fig. 18). Within the transmembrane domains the amino acid identity among any two of the three sequences is 73%. The most

dissimilar regions among any two of the three receptors are in the amino- and carboxy-terminal regions and in the second and third cytoplasmic loops. Within the amino terminus there is one consensus site for N-linked glycosylation for the

5 Xenopus melatonin receptor and the human Mel-1b receptor, while there are two sites in the amino terminus of the human Mel-1a receptor (Fig. 18, lower). The possibility of additional upstream translation start sites cannot be excluded.

10 Binding Studies of the Recombinant Human High-Affinity Mel-1b Receptor

Binding and pharmacological properties of the human Mel-1b receptor were examined by transiently expressing the receptor cDNA in COS-1 cells.

15 Expression studies were performed as follows. COS-1 and NIH 3T3 cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, penicillin (50 U/ml), and streptomycin (50 µg/ml), in 5% CO₂ at 37 °C. For ligand binding studies, 20 melatonin receptor cDNAs in pcDNA3 were introduced into COS-1 cells using the DEAE-dextran method (Cullen, B. (1987) Methods Enzymol. 152, 684-704). Three days after transfection, medium was removed, and the dishes were washed with PBS. The cells were harvested in Hank's balanced salt 25 solution and centrifuged (1400 x g; 10 min, 4°C). The resultant pellets were stored at -80°C. Crude membrane homogenates were prepared by thawing the pellets on ice and resuspending them in TME buffer (pH 7.4) consisting of 50 mM Tris base, 12.5 mM MgCl₂, 1mM EDTA, and supplemented with 30 10 µg/ml aprotinin and leupeptin, and 100 µM phenylmethylsulfonylfluoride. The cells were then

homogenized using a dounce homogenizer and centrifuged (45,000 x g; 15 min at 4°C). The resulting pellet was resuspended with a dounce homogenizer in TME and frozen at -80°C in aliquots.

5 Binding assays were performed in duplicate in a final volume of 200 µl, consisting of 20 µl radioligand, 20 µl TME containing either melatonin or displacer, and 160 µl membrane homogenates. Incubations were initiated by the addition of the membrane preparation and were conducted
10 at 37°C for 60 min. Nonspecific binding was defined by 10 µM melatonin. All determinations were done in either duplicate or triplicate.

15 Protein measurements were performed by the method of Bradford (Bradford, M.M. (1976) *Anal. Biochem.* 72, 248-254), using bovine serum albumin as the standard. Binding data were analyzed by computer using the LIGAND Program of Munson and Rodbard (Munson, P.J. and Rodbard, D. (1980) *Anal. Biochem.* 107, 220-239).

20 For comparison, binding and pharmacology of COS-1 cells transiently expressing the human Mel-1a receptor were assessed in parallel. Scatchard transformation of the saturation data showed that COS-1 cells transfected with either receptor bind ^{125}I -Mel with high affinity. The K_d of human Mel-1b receptor was $1.6 \pm 0.3 \times 10^{-11}$ M (mean + SE; n = 5 experiments) (Fig. 19). This value represents a 4-fold lower affinity than that of the human Mel-1a receptor ($K_d = 6.5 \pm 0.6 \times 10^{-11}$ M; n = 3) found in parallel experiments. The B_{max} values were 2.7 ± 0.1 pmol/mg membrane protein for human Mel-1b receptor and 2.8 ± 0.4 pmol/mg membrane protein
25 for the human Mel-1a receptor. The pharmacological characteristics for inhibition of specific $^{125}\text{IMel}$ binding in acutely transfected COS-1 cells were next examined for Mel-

1b receptor and compared with those of the human Mel-1a receptor (Fig. 20; Table 1).

TABLE 1

Competition of various ligands for specific ^{125}I -Mel binding
5 in COS-1 cells transfected with either human Mel-1b or the
Mel-1a receptor cDNA

10	Compound	K_i (nM)		Ratio (Mel-1a/Mel-1b)
		Mel-1b	Mel-1a	
2-iodomelatonin	0.17±0.02	0.09±0.01	0.5	
2-phenylmelatonin	0.26±0.06	0.21±0.06	0.8	
S20098	0.23±0.04	0.72±0.11	3.1	
6-chloromelatonin	0.66±0.04	6.78±0.91	10.3	
15 melatonin	1.11±0.13	1.48±0.21	1.3	
NAS	595±127	986±137	1.6	
5-HT	> 10,000	> 10,000	---	
prazosin	> 10,000	> 10,000	---	

20 K_i values are mean±SE of 3-5 experiments for each drug. NAS: N-acetyl-5-hydroxytryptamine. 5-HT: 5-hydroxytryptamine. S20098, a melatonin analog was obtained from Bristol-Myers Squibb, Princeton, NJ.

For human Mel-1b, the rank order of inhibition of specific ^{125}I -Mel binding by six ligands was 2-iodomelatonin
25 > 2-phenylmelatonin > S-20098 > 6-chloromelatonin >
melatonin > N-acetyl-5-hydroxytryptamine (Fig. 20a; Table 1). Micromolar concentrations of prazosin or
5-hydroxytryptamine did not inhibit specific ^{125}I -Mel binding. The rank order of inhibition of specific ^{125}I -Mel
30 binding for human Mel-1b receptor was very similar to that found in parallel experiments for the human Mel-1a melatonin receptor, except that 6chloromelatonin was 10-fold more

potent in inhibiting specific ^{125}I -Mel binding in cells expressing human Mel-1b receptor (Fig. 20b; Table 1). Thus, human Mel-1b receptor cDNA encodes a protein with ^{125}I -Mel binding characteristics that are quite similar to those of
5 the Mel-1a melatonin receptor.

Melatonin Inhibits cAMP Accumulation in Mel-1b-expressing Cells.

The recombinant Mel-1b receptor is coupled to inhibition of adenylyl cyclase as is the Mel-1a melatonin
10 receptor (Reppert, S.M. et al. (1994), supra).

For these studies, we used clonal lines of NIH 3T3 cells stably transfected with the receptor cDNA in pcDNA3. COS-1 and NIH 3T3 cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM) supplemented with
15 10% fetal calf serum, penicillin (50 U/ml), and streptomycin (50 $\mu\text{g}/\text{ml}$), in 5% CO₂ at 37°C.

For ligand binding studies, melatonin receptor cDNAs in pcDNA3 were introduced into COS-1 cells using the DEAE-dextran method (Cullen, B. (1987) supra). Three days after transfection, medium was removed, and the dishes were washed with PBS. The cells were harvested in Hank's balanced salt solution and centrifuged (1400 x g; 10 min, 4°C). The resultant pellets were stored at -80°C. Crude membrane homogenates were prepared by thawing the pellets on ice and resuspending them in TME buffer (pH 7.4) consisting of 50 mM Tris base, 12.5 mM MgCl₂, 1mM EDTA, and supplemented with 10 $\mu\text{g}/\text{ml}$ aprotinin and leupeptin, and 100 μM phenylmethylsulfonylfluoride. The cells were then homogenized using a dounce homogenizer and centrifuged
25 (45,000 x g; 15 min at 4°C). The resulting pellet was resuspended with a dounce homogenizer in TME and frozen at
30

• . . .

·80°C in aliquots. Binding assays were performed in
duplicate in a final volume of 200 μ l, consisting of 20 μ l
radioligand, 20 μ l TME containing either melatonin or
displacer, and 160 μ l membrane homogenates. Incubations were
5 initiated by the addition of the membrane preparation and
were conducted at 37°C for 60 min. Nonspecific binding was
defined by 10 μ M melatonin. All determinations were done in
either duplicate or triplicate. Protein measurements were
performed by the method of Bradford (Bradford, M.M. (1976)
10 supra), using bovine serum albumin as the standard. Binding
data were analyzed by computer using the LIGAND Program of
Munson and Rodbard (Munson, P.J. & Rodbard, D. (1980)
supra). For cAMP studies, the receptor cDNA in pcDNA3 was
introduced into NIH 3T3 cells using Lipofectamine
15 (GIBCO/BRL). Transformed NIH 3T3 cells resistant to
Geneticin, G418 (at 1.0 mg/ml; Gibco/BRL) were isolated and
single colonies expressing melatonin receptor binding (>200
fmol/mg total cellular protein) were isolated.

Transformed NIH 3T3 cells were plated in triplicate
20 on 35 mm dishes. Forty-eight hours later, the cells were
washed (2X) with DMEM and preincubated with 250 μ M
3-isobutyl-1-methylxanthine (IBMX) in DMEM for 10 min at
37°C. Cells were then incubated with or without drugs in
DMEM with 250 μ M IBMX for 10 min at 37°C. At the end of
25 treatment, the medium was aspirated and 0.5 ml of 50 mM
acetic acid was added. The cells were collected, transferred
to an Eppendorf tube, boiled for 5 min, and centrifuged
(13,750 rpm for 15 min). The supernatant was collected and
assayed for cAMP. All determinations were done in
30 triplicate. Cyclic AMP levels were determined in duplicate
by radioimmunoassay (New England Nuclear). 125 I-Mel was
purchased from New England Nuclear. All drugs used in

competition studies were purchased from Sigma, Research Biochemicals or were synthesized by standard methods. All other chemicals were purchased from Sigma.

Results of these studies showed that melatonin
5 (1 μ M) did not increase basal cAMP levels in stably transfected NIH 3T3 cells. Melatonin did cause a dose-dependent inhibition of the increase in cAMP accumulation induced by 10 μ M forskolin (Fig. 21); the maximal inhibition of the mean forskolin stimulated cAMP value was at 10⁻⁸ M
10 melatonin. The estimated IC₅₀ value of this response (ca. 1 \times 10⁻⁹ M) was very similar to the computer generated K_i value (1.11 \pm 0.13 \times 10⁻⁹ M) determined for melatonin inhibition of specific ¹²⁵I-Mel binding (Fig. 20; Table 1). Thus, the
15 recombinant melatonin-1b receptor is negatively coupled to the cAMP regulatory system.

Characteristics of the Human High Affinity Mel-1b Receptor Gene and its Expression

Restriction endonuclease mapping and PCR analysis of genomic clones showed that the portion of the gene that
20 encodes the coding region of human Mel-1b receptor is comprised of two exons, separated by an intron that is approximately 9.0 kb in length. Southern analysis of human genomic DNA digested with several different restriction endonucleases was performed using a PCR-fragment of the
25 second exon of human Mel-1b DNA as a hybridization probe. Under high stringency conditions, a pattern of single bands was observed, suggesting that human Mel-1b receptor is encoded by a single copy gene.

To localize the gene for human Mel-1b, an intronic
30 PCR assay was developed that would amplify only the human Mel-1b receptor gene. A panel of 43 human-rodent somatic

cell hybrids that contained defined overlapping subsets of human chromosomes was screened (Geissler, E.N., Liao, M., Brook, J.D., Martin, F.H., Zsebo, K.M., Housman, D.E. & Galli, S.J. (1991) *Somatic Cell Genet.* 17, 207-214;

5 Pelletier, J., Brook, D.J. & Housman, D.E. (1991) *Genomics* 10, 1079-1082; NIGMS Mapping Panel #2, Coriell Institute, Camden, NJ). Using primer 5'-CTGTGCCTCTAAGAGCCACTTGGTTTC-3' (SEQ ID NO:19) and primer 5'TATTGAAGACAGAGCCGATGACGCTCA3' (SEQ ID NO:29), PCR amplified

10 a single band only in those cell lines containing human chromosome 11. The Mel-1b receptor gene was further localized to band 11q21-22 by PCR screening of a panel of somatic cell hybrids containing various deletion fragments of human chromosome 11 (Glaser, T., Housman, D., Lewis, W.H., Gerhard, D. & Jones, C. (1989) *Somat. Cell. Mol. Genet.* 15, 477-501; Fig. 23). The gene encoding human Mel-1b receptor has been given the designation *MTNRI B*.

To assess the tissue distribution of human Mel-1b mRNA, comparative RT-PCR analysis was performed using a modification of a previously described procedure (Kelly, M.R., Jurgens, J.K., Tentler, J., Emanuele, N.V., Blutt, S.E., Emanuele, M.A. (1993) *Alcohol* 10: 185-189). Poly(A)⁺ RNA was purchased from Clontech and 2 µg from each tissue was primed with random hexamers and reverse transcribed as previously described (Reppert, S.M., Weaver D.R., Stehle, J.H. & Rivkees, S.A. (1991) *Mol. Endocrinol.* 5:1037-1048). The cDNA was subjected to 25 cycles of amplification with 200 nM each of two specific primers.

The Mel-1b and Mel-1a receptor primers were designed so that they would amplify cDNA across the intron splice sites in the first cytoplasmic loop. Since the introns for both the Mel-1b and Mel-1a receptor genes are large (> 8

kb), amplification of the appropriate sized cDNA fragments would eliminate the possibility of amplification of genomic DNA. The human Mel-1b receptor primers were
5'-TCCTGGTGATCCTCTCCGTGCTCA-3' (SEQ ID NO:20) and
5 5'-AGCCAGATGAGGCAGATGTGCAGA-3' (SEQ ID NO:21), and amplified a band of 321 bp. The Mel-1a receptor primers were
5'-TCCTGGTCATCCTGTCGGTGTATC-3' (SEQ ID NO:22) and
5'-CTGCTGTACAGTTGTCGTACTTG-3' (SEQ ID NO:23), and amplified a band of 285 bp. Histone-H3.3 served as a control to verify
10 the amount of template for each sample. The histone H3.3 primers were 5'-GCAAGAGTGCGCCCTCTACTG-3' (SEQ ID NO:24) and 5'-GGCCTCACTTGCCTCCTGCAA-3' (SEQ ID NO:25), and amplified a band of 217 bp.

After PCR, the reaction products were subjected to electrophoresis through a 1.5% agarose gel and blotted onto GeneScreen (New England Nuclear). To increase the specificity of the assay, blots were hybridized with 25-mer oligonucleotides, labeled with [γ -32P]ATP by T4 polynucleotide kinase. For each primer pair, the
20 oligonucleotide probes were specific for a sequence of the amplified fragment between the primers. Oligonucleotide sequences were 5'-CTAACCTCGTGGCCAATCTTCTATG-3' (SEQ ID NO:26) for human Mel-1b receptor;
5'-TTGGTGCTGATGTCGATATTAACA-3' (SEQ ID NO:27) for the human
25 Mel-1a receptor; and 5'-CACTGAACCTCTGATTGCGAAACTT-3' (SEQ ID NO:28) for histoneH3.3. Hybridizing conditions were 45°C overnight in 0.5 M NaPO₄ (pH 7.2), 7% SDS, 1% BSA and 1mM EDTA. The blots were washed twice in 0.2 M NaPO₄, 1% SDS and 1 mM EDTA at 45°C for 30 min.

30 A 364 bp fragment of the rat homolog of the human Mel-1b receptor cDNA was cloned by RT-PCR from rat brain RNA; the rat cDNA fragment was 81% identical at the amino

acid level with human Mel-1b receptor. The rat fragment was used to probe a Northern blot containing 5 µg poly(A)⁺ RNA from each of 20 different rat tissues. No positive hybridization signals were found. Furthermore, *in situ* hybridization using an antisense cRNA probe to the rat fragment did not reveal a hybridization signal in PT or SCN, sites which gave a positive hybridization signal in the same *in situ* run using an antisense cRNA probe to the Mel-1a receptor (Reppert, S.M., Weaver, D.R. & Ebisawa, T. (1994) 10 Neuron 13, 1177-1185).

Because of the apparent low level of receptor transcripts, a comparative RT-PCR assay was used to examine the expression of human Mel-1b and Mel-1a receptor genes in 6 human tissues (Fig. 22). Human Mel-1b receptor was 15 expressed in retina, with much lower expression in whole brain and hippocampus. The human Mel-1a receptor was clearly expressed in whole brain, with just detectable expression in retina and hippocampus. Neither Mel-1b nor Mel-1a receptor mRNA was detected in pituitary, liver or 20 spleen. To ensure consistency in the amount of RNA reverse transcribed and the efficiency of the reverse transcription reactions among the tissues examined, the histone H3.3 cDNA was amplified from each tissue examined; very comparable amplifications occurred among the six tissues (Fig. 22).

25 Relative Characteristics of the Human High Affinity Mel-1a and Mel-1b Receptors

One feature that distinguishes the Mellb-receptor from the Mel-1a receptor is its tissue distribution. The substantially greater expression of the Mel-1b receptor in 30 retina suggests that melatonin may exert its effects on mammalian retinal physiology through this receptor.

Melatonin inhibits the Ca^{+2} -dependent release of dopamine in rabbit retina through activation of receptors with pharmacologic specificity comparable with that reported here for the Mel-1b receptor (Dubocovich, M.L. & Takahashi, J. 5 (1987) Proc. Natl. Acad. Sci. USA 84, 3916-3920; Dubocovich, M.L. (1983) Nature 306, 782-4). Melatonin appears to act in the retina to affect several light-dependent functions, including photopigment disc shedding and phagocytosis (Besharse, J.C. & Dunis, D.A. (1983) Science 219:1341-1343; 10 Cahill, G.M., Grace, M.S. & Besharse, J.C. (1991) Cell. Mol. Neurobiol. 11:529-560).

The discovery of the Mel-1b receptor which has similar binding and functional characteristics to those of the Mel-1a receptor make it conceivable that the Mel-1b receptor also participates in the circadian and/or reproductive actions of melatonin. Even though Mel-1b receptor mRNA is not detectable by *in situ* hybridization in rat SCN or PT, it may be present and functional in these or other neural sites at levels not detectable using standard 15 detection methods.

A second distinguishing feature of the Mel-1b receptor is its chromosome location. The Mel-1b melatonin receptor maps to human chromosome 11q21-22, a region syntenic to mouse chromosome 9 in the region of the 20 D_2 -dopamine receptor (*Drd2*) and thymus cell antigen 1 (*Thy1*) loci (Goldsborough et al. (1993) Nucl. Acids Res. 21:127-132; Seldin, M.F., Saunders, A.M., Rochelle, J.M. and Howard, T.A. (1991) Genomics 9:678-685). This contrasts with the Mel-1a receptor which maps to human chromosome 4q35.1 25 and mouse chromosome 8. Thus, these two structurally and functionally related melatonin receptors did not merely 30 evolve by simple tandem duplication of an ancestral gene,

but suggests that other mechanisms, such as chromosomal rearrangement and duplication, were involved.

The discovery of a new member of the G protein-coupled, melatonin receptor family shows that at least two distinct genes have evolved to subserve melatonin's functions. The development of a method of identifying pharmacological agents which selectively affect Mel-1a and Mel-1b receptor function is an important therapeutic application made available by the disclosed invention.

Relative Characteristics of the *Xenopus* and Mammalian Melatonin-1a High-Affinity Receptors

Acute transfection of COS-7 cells with the *Xenopus* melatonin receptor and the sheep Mel-1a receptor clones results in transient expression of receptors that bind ^{125}I -melatonin with high affinity (Fig. 9 and Fig. 12b). Additionally, specific ^{125}I -melatonin binding to *Xenopus* receptor transiently expressed in cells is inhibited by six ligands in a rank order that is identical to that reported for the endogenous Mel-1a receptor in reptiles, birds, and mammals (Fig. 9) (Dubocovich et al. (1987), supra; Rivkees et al. (1989), supra; Morgan, P.J. et al. (1989) supra). The ability of the recombinant *Xenopus* high-affinity melatonin receptor to inhibit the forskolin-stimulated increase in cAMP accumulation in stably transfected CHO cells is consistent with studies of the endogenous receptor which show that a major signal transduction pathway for the high-affinity Mel -1a receptor is inhibition of adenylyl cyclase (Abe, K. et al. (1969), supra; White et al. (1987), supra). Finally, *Xenopus* melatonin receptor mRNA is moderately expressed in the cells whose RNA was used to

generate the cDNA library. Thus, the cloned receptor likely mediates the potent effects of melatonin on pigment aggregation in frog melanophores. Structurally, the protein encoded by the melatonin receptor cDNA defines a new 5 receptor group within the large superfamily of G protein-coupled receptors.

Previous studies using quantitative ^{125}I -Mel autoradiography in the human SCN have generally shown high affinity for melatonin and 6-chloromelatonin and very low 10 affinity for serotonin (Reppert et al., (1988) *supra*), all consistent with the pharmacological characteristics of the recombinant human receptor (Fig. 15). The pharmacological characteristics of the recombinant sheep Mel-1a receptor are virtually identical to those of the endogenous melatonin 1a 15 receptor in sheep PT (Morgan et al., *J. Endocrinol.* (1989) 1:1-4). The difference between the sheep and human Mel-1a receptors in their affinities for 6-chloromelatonin is reproducible and equally apparent when the sheep and human Mel-1a receptors are examined in the same assay run.

20 Polypeptide Expression

Polypeptides according to the invention may be produced by transformation of a suitable host cell with all or part of a high-affinity melatonin receptor-encoding cDNA fragment (e.g., the cDNAs described above) in a suitable 25 expression vehicle, and expression of the receptor.

Those skilled in the field of molecular biology will understand that any of a wide variety of expression systems may be used to provide the recombinant receptor protein. The precise host cell used is not critical to the invention. 30 The receptor may be produced in a prokaryotic host (e.g., *E. coli*) or in a eukaryotic host (e.g., *Saccharomyces*

cerevisiae or mammalian cells, e.g., COS-6M, COS-7 NIH/3T3, or Chinese Hamster Ovary cells). Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Rockville, MD). The method of transfection and the choice of expression vehicle will depend on the host system selected. Transformation and mammalian cell transfection methods are described, e.g., in Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989)); expression vehicles may be chosen from those provided, e.g., in Cloning Vectors: A Laboratory Manual (Pouwels, P.H. et al., (1985), Supp. 1987).

One particularly preferred expression system is the Chinese hamster ovary (CHO) cell (ATCC Accession No. CCL 61) transfected with a pcDNAI/NEO expression vector (InVitrogen, San Diego, CA). pcDNAI/NEO provides an SV40 origin of replication which allows replication in mammalian systems, a selectable neomycin gene, and SV40 splicing and polyadenylation sites. DNA encoding the human, sheep, or *Xenopus* high-affinity melatonin receptor or an appropriate receptor fragment or analog (as described above) would be inserted into the pcDNAI/NEO vector in an orientation designed to allow expression. Other preferable host cells which may be used in conjunction with the pcDNAI/NEO expression vehicle include NIH/3T3 cells (ATCC Accession No. 1658). The expression may be used in a screening method of the invention (described below) or, if desired, the recombinant receptor protein may be isolated as described below.

Alternatively, the high-affinity melatonin receptor (or receptor fragment or analog) is expressed by a stably-transfected mammalian cell line.

A number of vectors suitable for stable transfection of mammalian cells are available to the public, e.g., see Pouwels et al. (supra); methods for constructing such cell lines are also publicly available, e.g., in Ausubel et al. (5 supra). In one example, cDNA encoding the receptor (or receptor fragment or analog) is cloned into an expression vector which includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid and, therefore, the high-affinity melatonin receptor-encoding gene into the host cell 10 chromosome is selected for by inclusion of 0.01-300 μ M methotrexate in the cell culture medium (as described in Ausubel et al., supra). This dominant selection can be accomplished in most cell types. Recombinant protein expression can be increased by DHFR-mediated amplification 15 of the transfected gene. Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al. (supra); such methods generally involve extended culture in medium containing gradually increasing levels of methotrexate. DHFR-containing expression vectors commonly 20 used for this purpose include pCVSEII-DHFR and pAdD26SV(A) (described in Ausubel et al., supra). Any of the host cells described above or, preferably, a DHFR-deficient CHO cell line (e.g., CHO DHFR cells, ATCC Accession No. CRL 9096) are among the host cells preferred for DHFR selection of a 25 stably-transfected cell line or DHFR-mediated gene amplification.

One particularly preferred stable expression system is a CHO cell (ATCC) stably transfected with a pcDNAI/NEO (Invitrogen, San Diego, CA) expression vector.

30 Expression of the recombinant receptor (e.g., produced by any of the expression systems described herein) may be assayed by immunological procedures, such as Western blot or immunoprecipitation analysis of recombinant cell

extracts, or by immunofluorescence of intact recombinant cells (using, e.g., the methods described in Ausubel et al., supra). Recombinant receptor protein is detected using an antibody directed to the receptor. Described below are
5 methods for producing high-affinity melatonin receptor antibodies using, as an immunogen, the intact receptor or a peptide which includes a suitable high-affinity melatonin receptor epitope. To detect expression of a high-affinity melatonin receptor fragment or analog, the antibody is
10 preferably produced using, as an immunogen, an epitope included in the fragment or analog.

Once the recombinant high-affinity melatonin receptor protein (or fragment or analog, thereof) is expressed, it is isolated, e.g., using immunoaffinity chromatography. In one example, an anti-high-affinity melatonin receptor antibody may be attached to a column and used to isolate intact receptor or receptor fragments or analogs. Lysis and fractionation of receptor-harboring cells prior to affinity chromatography may be performed by
15 standard methods (see, e.g., Ausubel et al., supra). Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques In Biochemistry And Molecular Biology, eds., Work and Burdon,
20 Elsevier, (1980)).

Receptors of the invention, particularly short receptor fragments, can also be produced by chemical synthesis (e.g., by the methods described in Solid Phase Peptide Synthesis, (1984) 2nd ed., The Pierce Chemical Co.,
30 Rockford, IL).

Assays for High-Affinity Melatonin Receptor Function

Useful receptor fragments or analogs in the invention are those which interact with melatonin. Such an interaction may be detected by an *in vitro* functional assay (e.g., the cAMP accumulation assay described herein). This assay includes, as components, forskolin for induced cAMP accumulations, melatonin, and a recombinant high-affinity melatonin receptor (or a suitable fragment or analog) configured to permit melatonin binding (e.g., those polypeptides described herein). Melatonin and forskolin may be obtained from Sigma (St. Louis, MO) or similar supplier.

Preferably, the high-affinity melatonin receptor component is produced by a cell that naturally presents substantially no receptor on its surface, e.g., by engineering such a cell to contain nucleic acid encoding the receptor component in an appropriate expression system. Suitable cells are, e.g., those discussed above with respect to the production of recombinant receptor, such as CHO cells or COS-7 cells.

Screening For High-Affinity Melatonin Receptor Antagonists and Agonists

As discussed above, one aspect of the invention features screening for compounds that antagonize the interaction between melatonin and the high-affinity melatonin receptor, thereby preventing or reducing the cascade of events that are mediated by that interaction. The elements of the screen are forskolin to induce intracellular accumulation of cAMP, melatonin, and recombinant high-affinity receptor (or a suitable receptor fragment or analog, as outlined above) configured to permit detection of melatonin function. As described above, melatonin and forskolin may be purchased from Sigma, and a full-length sheep Mel-1a receptor or *Xenopus* high-affinity

melatonin receptor, or a human high-affinity melatonin 1a or 1b receptor (or a melatonin-binding fragment or analog of the *Xenopus*, sheep or human receptors) may be produced as described herein. Preferably, such a screening assay is
5 carried out using cell lines stably transfected with the high-affinity melatonin receptor. Most preferably, the untransfected cell line presents substantially no receptor on its cell surface.

Activation of the heterologous high-affinity
10 melatonin receptor with melatonin or an agonist (see above) leads to reduction of intracellular cAMP concentration, providing a convenient means for measuring melatonin or agonist activity. Such an agonist may be expected to be a useful therapeutic agent for circadian rhythm disorders such
15 as jet lag, day/night cycle disorders in humans or mating cycle alterations in animals such as sheep. Appropriate candidate agonists include melatonin analogs or other agents which mimic the action of melatonin.

Inclusion of potential antagonists in the screening
20 assay along with melatonin allows for the screening and identification of authentic receptor antagonists as those which decrease melatonin-mediated intracellular cAMP reduction. Receptor bearing cells incubated with forskolin (for initial induction cAMP concentration) or melatonin
25 (alone, i.e., in the absence of inhibitor) are used as a "control" against which antagonist assays are measured.

Appropriate candidate antagonists include high-affinity melatonin receptor fragments, particularly, fragments of the protein predicted to be extracellular (see
30 Fig. 7) and therefore likely to bind melatonin; such fragments would preferably include five or more amino acids. Other candidate antagonists include melatonin

analog as well as other peptide and non-peptide compounds and anti-high-affinity melatonin receptor antibodies.

Another aspect of the invention features screening for compounds that act as high-affinity melatonin receptor agonists; such compounds are identified as those which bind a high-affinity melatonin receptor and mimic the cascade of events that are normally mediated by that interaction. This screen requires recombinant cells expressing recombinant high-affinity melatonin receptor (or a suitable receptor fragment or analog, as outlined herein) configured to permit detection of high-affinity melatonin receptor function. In one example, a candidate agonist is added to CHO cells stably expressing recombinant receptor and intracellular cAMP levels are measured (as described above). An agonist useful in the invention is one which imitates the normal melatonin-mediated signal transduction pathway leading, e.g., to a decrease in intracellular cAMP concentration.

Appropriate candidate agonists include melatonin analogs or other chemical agents capable of mimicking the action of melatonin.

Preparation of a Transgenic Animal Containing Recombinant Melatonin-1a and/or Melatonin-1b Genes

There are several means by which transgenic animals can be made. A transgenic animal (such as a mammal) may be constructed by one of several techniques, including targeted insertion of an exogenous melatonin receptor gene into the endogenous gene of the animal, or other methods well known to those skilled in the art.

A transgenic mammal whose germ cells and somatic cells contain an exogenous melatonin-1a or melatonin-1b receptor gene is produced by methods known in the art. See, for example, U. S. Patent No. 4,736,866 describing

production of a transgenic mammal, herein incorporated by reference. Generally, the DNA sequence encoding an exogenous melatonin-1a or -1b receptor gene is introduced into the animal, or an ancestor of the animal, at an 5 embryonic stage (preferably the one-cell, or fertilized oocyte, stage, and generally not later than about the 8-cell stage). There are several methods known to the art of introducing a foreign gene into an animal embryo to achieve stable expression of the foreign gene. One method is to 10 transfect the embryo with the gene as it occurs naturally, and select transgenic animals in which the foreign gene has integrated into the genome at a locus which results in its expression. Other methods involve modifying the foreign gene or its control sequences prior to introduction into the 15 embryo. For example, the melatonin-1a or -1b receptor gene may be modified with an enhanced, inducible, or tissue-specific promoter.

Tissues of transgenic mammals are analyzed for the presence of exogenous melatonin-1a or -1b receptor, either 20 by directly analyzing mRNA, or by assaying the tissue for exogenous melatonin-1a or -1b receptor.

Using the Transgenic Mammal to Determine Melatonin Agonist- or Antagonist-Related Effects

The animals described above can be used to determine 25 whether candidate compounds are melatonin antagonists or agonists for the Mel-1a or Mel-1b receptors.

Assessing Melatonin Agonists or Antagonists *in vivo*

One aspect of the invention features screening for 30 compounds that agonize or antagonize melatonin activity *in vivo*. The elements of the screen are a Mel-1a or Mel-1b transgenic mammal and a potential melatonin agonist or antagonist in a suitable formulation for administration to

the mammal. Detection of a change in the phenotype of interest (e.g., sleep/wake cycle or reproductive cycle) relative to a control transgenic mammal to which no agonist or antagonist has been administered indicates a potentially useful candidate compound.

Anti-High-Affinity Melatonin Receptor Antibodies

High-affinity melatonin receptor (or immunogenic receptor fragments or analogs) may be used to raise antibodies useful in the invention. As described above, receptor fragments preferred for the production of antibodies are those fragments deduced or shown experimentally to be extracellular.

Antibodies directed to high-affinity melatonin receptor peptides are produced as follows. Peptides corresponding to all or part of the putative extracellular loops or the extracellular N-terminal domain are produced using a peptide synthesizer, by standard techniques. The peptides are coupled to KLH with m-maleimide benzoic acid N-hydroxysuccinimide ester. The KLH-peptide is mixed with Freund's adjuvant and injected into animals, e.g. guinea pigs or goats, to produce polyclonal antibodies. Monoclonal antibodies may be prepared using the high-affinity melatonin polypeptides described above and standard hybridoma technology (see, e.g., Kohler et al., Nature (1975) 256:495, 1975; Kohler et al., Eur. J. Immunol. (1976) 6:292; Kohler et al., Eur. J. Immunol. (1976) 6:511; Hammerling et al., in Monoclonal Antibodies and T Cell Hybridomas, Elsevier, NY, (1981); and Ausubel et al., supra). Antibodies are purified by peptide antigen affinity chromatography.

Once produced, antibodies are tested for specific high-affinity melatonin receptor recognition by Western blot

or immunoprecipitation analysis (by the methods described in Ausubel et al., supra).

Antibodies which specifically recognize the high-affinity melatonin receptor are considered to be likely candidates for useful antagonists; such candidates are further tested for their ability to specifically interfere with the interaction between melatonin and its receptor (using the functional antagonist assays described herein). Antibodies which antagonize melatonin: high-affinity melatonin receptor binding or high-affinity melatonin receptor function are considered to be useful as antagonists in the invention.

Therapy

Particularly suitable therapeutics for the treatment of circadian rhythm disorders in humans as well as for regulating changes in the reproductive cycle of seasonally breeding animals are the agonists and antagonists described above formulated in an appropriate buffer such as physiological saline. Where it is particularly desirable to mimic a receptor fragment conformation at the membrane interface, the fragment may include a sufficient number of adjacent transmembrane residues. In this case, the fragment may be associated with an appropriate lipid fraction (e.g., in lipid vesicles or attached to fragments obtained by disrupting a cell membrane). Alternatively, anti-high-affinity melatonin receptor antibodies produced as described above may be used as a therapeutic. Again, the antibodies would be administered in a pharmaceutically-acceptable buffer (e.g., physiological saline). If appropriate, the antibody preparation may be combined with a suitable adjuvant.

The therapeutic preparation is administered in accordance with the condition to be treated. Ordinarily, it will be administered intravenously, at a dosage, of a duration, and with the appropriate timing to elicit the desired response. Appropriate timing refers to the time in the natural circadian rhythm at which administration of therapeutic preparation elicits the desired response. Alternatively, it may be convenient to administer the therapeutic orally, nasally, or topically, e.g., as a liquid or a spray. Again, the dosages are as described above. Treatment may be repeated as necessary for alleviation of disease symptoms.

High-affinity melatonin receptor agonists can be used to retrain the endogenous melatonin rhythm of humans; alleviate jet lag symptoms in humans; phase shift the sleep/wake cycle of some blind people, reinforce entrainment of endogenous melatonin rhythm using low intensity light/dark cycle; control ovulation in humans; and alter reproductive cycles in seasonally breeding animals. Antagonists may be useful in controlling the initiation or timing of puberty in humans.

The methods of the invention may be used to screen therapeutic receptor agonists and antagonists for their effectiveness in reducing intracellular cAMP production *in vitro*; in altering circadian rythmn; or in altering reproductive cycles by the assays described above. Where a non-human mammal is treated or where a therapeutic for a non-human animal is screened, the high-affinity melatonin receptor or receptor fragment or analog or the antibody employed is preferably specific for that species.

Other Embodiments

. . . .

Polypeptides according to the invention include any high-affinity melatonin receptors (as described herein). Such receptors may be derived from any source, but are preferably derived from a vertebrate animal, e.g., a human, 5 a sheep, or a frog. These polypeptides are used, e.g., to screen for antagonists which disrupt, or agonists which mimic, a melatonin:receptor interaction (see above).

Polypeptides of the invention also include any analog or fragment of a high-affinity melatonin receptor 10 capable of interacting with melatonin (e.g., those derived from the high-affinity melatonin receptor extracellular domains). Such analogs and fragments may also be used to screen for high-affinity melatonin receptor antagonists or agonists. In addition, that subset of receptor fragments or 15 analogs which bind melatonin and are, preferably, soluble (or insoluble and formulated in a lipid vesicle) may be used as antagonists to reduce the amplitude of the endogenous melatonin cycle possibly providing for the induction of puberty in humans. The efficacy of a receptor analog or 20 fragment is dependent upon its ability to interact with melatonin; such an interaction may be readily assayed using high-affinity melatonin receptor functional assays (e.g., those described herein).

Specific receptor analogs of interest include full-length or partial receptor proteins including an amino acid sequence which differs only by conservative amino acid substitutions, for example, substitution of one amino acid for another of the same class (e.g., valine for glycine, arginine for lysine, etc.) or by one or more non- 25 conservative amino acid substitutions, deletions, or insertions located at positions of the amino acid sequence 30 which do not destroy the receptors' ability to signal

melatonin-mediated reduction in intracellular cAMP concentration (e.g., as assayed above).

Specific receptor fragments of interest include any portion of the high-affinity melatonin receptor which is

5 capable of interacting with melatonin, for example, all or part of the extracellular domains (described above). Such fragments may be useful as antagonists (as described above), and are also useful as immunogens for producing antibodies which neutralize the activity of the high-affinity melatonin
10 receptor *in vivo* (e.g., by interfering with the interaction between the receptor and melatonin; see below).

Extracellular regions of novel high-affinity melatonin receptors may be identified by comparison with related proteins of similar structure (e.g., other members of the G-protein-coupled receptor superfamily); useful regions are those exhibiting homology to the extracellular domains of well-characterized members of the family.

Alternatively, from the primary amino acid sequence, the secondary protein structure and, therefore, the extracellular domain regions may be deduced semi-empirically using a hydrophobicity/hydrophilicity calculation such as the Chou-Fasman method (see, e.g., Chou and Fasman, Ann. Rev. Biochem. (1978) 47:251). Hydrophilic domains, particularly ones surrounded by hydrophobic stretches (e.g., transmembrane domains) present themselves as strong candidates for extracellular domains. Finally, extracellular domains may be identified experimentally using standard enzymatic digest analysis, e.g., tryptic digest analysis.

30 Candidate fragments (e.g., any extracellular fragment) are tested for interaction with melatonin by the assays described herein (e.g., the assay described above). Such fragments are also tested for their ability to

antagonize the interaction between melatonin and its endogenous receptor using the assays described herein. Analogs of useful receptor fragments (as described above) may also be produced and tested for efficacy as screening 5 components or antagonists (using the assays described herein); such analogs are also considered to be useful in the invention.

Other embodiments are within the claims.

What is claimed is:

Claims

1 1. Substantially pure DNA encoding a high-affinity
2 melatonin receptor.

1 2. The DNA of claim 1, wherein said DNA is genomic
2 DNA.

1 3. The DNA of claim 1, wherein said DNA is cDNA.

1 4. The DNA of claim 1, wherein said DNA is
2 mammalian.

1 5. Substantially pure DNA having the sequence of
2 Fig. 1 (SEQ ID NO:1), or degenerate variants thereof, and
3 encoding the amino acid sequence of Fig. 1 (SEQ ID NO:2).

1 6. Substantially pure DNA having the sequence of
2 Fig. 2 (SEQ ID NO:3), or degenerate variants thereof, and
3 encoding the amino acid sequence of Fig. 2 (SEQ ID NO:4).

1 7. Substantially pure DNA comprising the DNA
2 sequence of Fig. 4 (SEQ ID NO:5), or degenerate variants
3 thereof, and encoding an amino acid sequence comprising the
4 amino acid sequence of Fig. 4 (SEQ ID NO:6).

1 8. Substantially pure DNA comprising the DNA
2 sequence of Fig. 5 (SEQ ID NO:11), or degenerate variants
3 thereof, and encoding an amino acid sequence comprising the
4 amino acid sequence of Fig. 5 (SEQ ID NO:12).

1 9. Substantially pure DNA comprising the DNA
2 sequence of Fig. 3 (SEQ ID NO:13), or degenerate variants
3 thereof, and encoding an amino acid sequence comprising the
4 amino acid sequence of Fig. 3 (SEQ ID NO:14).

1 10. Substantially pure DNA comprising the DNA
2 sequence of Fig. 6 (SEQ ID NO:15), or degenerate variants
3 thereof, and encoding an amino acid sequence comprising the
4 amino acid sequence of Fig. 6 (SEQ ID NO:16).

1 11. Substantially pure DNA having 50% or greater
2 sequence identity to the DNA sequence of Fig. 2 (SEQ ID
3 NO:3) and encoding a protein capable of binding melatonin.

1 12. Substantially pure DNA which hybridizes to the
2 DNA sequence of Fig. 1 (SEQ ID NO:1) under conditions of
3 high stringency.

1 13. Substantially pure DNA which hybridizes to the
2 DNA sequence of Fig. 2 (SEQ ID NO:3) under conditions of
3 high stringency.

1 14. Substantially pure DNA which hybridizes to the
2 DNA sequence of Fig. 4 (SEQ ID NO:5) under conditions of
3 high stringency.

1 15. Substantially pure DNA which hybridizes to the
2 DNA sequence of Fig. 5 (SEQ ID NO:11) under conditions of
3 high stringency.

1 16. Substantially pure DNA which hybridizes to the
2 DNA sequence of Fig. 3 (SEQ ID NO:13) under conditions of
3 high stringency.

1 17. Substantially pure DNA which hybridizes to the
2 DNA sequence of Fig. 6 (SEQ ID NO:15) under conditions of
3 high stringency.

1 18. Substantially pure high-affinity melatonin
2 receptor protein.

1 19. The receptor protein of claim 18, having an
2 amino acid sequence substantially identical to the amino
3 acid sequence shown in Fig. 1 (SEQ ID NO:2).

1 20. The receptor protein of claim 18, having an
2 amino acid sequence substantially identical to the amino
3 acid sequence shown in Fig. 2 (SEQ ID NO:4).

1 21. The receptor protein of claim 18, comprising
2 the amino acid sequence of Fig. 3 (SEQ ID NO:6).

1 22. The receptor protein of claim 18, having an
2 amino acid sequence substantially identical to the amino
3 acid sequence shown in Fig. 4 (SEQ ID NO:12).

1 23. The receptor protein of claim 18, having an
2 amino acid sequence substantially identical to the amino
3 acid sequence shown in Fig. 3 (SEQ ID NO:14).

1 24. The receptor protein of claim 14, having an
2 amino acid sequence substantially identical to the amino
3 acid sequence shown in Fig. 6 (SEQ ID NO:16).

1 25. A substantially pure polypeptide having an
2 amino acid sequence which is at least 80% identical to the
3 amino acid sequence shown in Fig. 1 (SEQ ID NO:2), wherein
4 a) said polypeptide binds melatonin; and
5 b) said polypeptide mediates a decrease in
6 intracellular cAMP concentration in a cell expressing said
7 polypeptide on its surface.

1 26. A substantially pure polypeptide having an
2 amino acid sequence which is at least 80% identical to the
3 amino acid sequence shown in Fig. 2 (SEQ ID NO:4), wherein
4 a) said polypeptide binds melatonin; and
5 b) said polypeptide mediates a decease in
6 intracellular cAMP concentration in a cell expressing said
7 polypeptide on its surface.

1 27. A substantially pure polypeptide having an
2 amino acid sequence which is at least 80% identical to the
3 amino acid sequence shown in Fig. 5 (SEQ ID NO:12), wherein
4 a) said polypeptide binds melatonin; and
5 b) said polypeptide mediates a decease in
6 intracellular cAMP concentration in a cell expressing said
7 polypeptide on its surface.

1 28. A substantially pure polypeptide having an
2 amino acid sequence which is at least 80% identical to the
3 amino acid sequence shown in Fig. 3 (SEQ ID NO:14), wherein
4 a) said polypeptide binds melatonin; and
5 b) said polypeptide mediates a decrease in
6 intracellular cAMP concentration in a cell expressing said
7 polypeptide on its surface.

1 29. A substantially pure polypeptide having an
2 amino acid sequence which is at least 80% identical to the
3 amino acid sequence shown in Fig. 6 (SEQ ID NO:16), wherein
4 a) said polypeptide binds melatonin; and
5 b) said polypeptide mediates a decrease in
6 intracellular cAMP concentration in a cell expressing said
7 polypeptide on its surface.

1 30. A substantially pure polypeptide which is a
2 fragment or analog of a high-affinity melatonin receptor
3 comprising a domain capable of binding melatonin and
4 mediating a decrease in intracellular cAMP concentration.

1 31. A vector comprising the DNA of claim 1.

1 32. A cell which contains the DNA of claim 1.

1 33. A method of testing a candidate compound for
2 the ability to act as an agonist of a high affinity
3 melatonin receptor ligand, said method comprising:

4 a) contacting said candidate compound with a cell
5 which expresses on its surface a recombinant high-affinity
6 melatonin receptor protein or melatonin binding fragment or
7 analog thereof;

8 b) measuring intracellular cAMP concentration in
9 said cell; and

10 c) identifying said candidate compound as an agonist
11 where said contacting causes a decrease in intracellular
12 cAMP concentration.

1 34. A method of testing a candidate compound for
2 the ability to act as an antagonist of a high affinity
3 melatonin receptor ligand, said method comprising:

4 a) contacting said candidate compound with a cell
5 which expresses on its surface a recombinant high-affinity
6 melatonin receptor protein or melatonin binding fragment or
7 analog thereof;

8 b) measuring binding between said receptor protein
9 and melatonin; and

10 c) identifying said candidate compound as an
11 antagonist where said contacting causes a decrease in
12 binding between said recombinant high-affinity melatonin
13 receptor protein and melatonin.

1 35. The method of claim 25 or 26, wherein said cell
2 is a mammalian cell which normally presents substantially no
3 high-affinity melatonin receptor on its surface.

1 36. A therapeutic composition comprising as an
2 active ingredient high-affinity melatonin receptor agonist,
3 said active ingredient being formulated in a
4 physiologically-acceptable carrier.

HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF

Abstract of the Disclosure

Disclosed are cDNAs and DNAs encoding high-affinity melatonin 1a and 1b receptors and the recombinant polypeptides expressed from such cDNAs. The recombinant receptor polypeptides, receptor fragments and analogs expressed on the surface of cells are used in methods of screening candidate compounds for their ability to act as agonists or antagonists to the effects of interaction between melatonin and high-affinity melatonin receptor. Agonists are used as therapeutics to retrain endogenous melatonin rhythms as a means of treating circadian rhythm disorders in humans and control reproductive cycles in seasonally breeding animals. Antagonists are used as therapeutics to control the initiation or timing of puberty in humans. Antibodies specific for a high-affinity melatonin receptor (or receptor fragment or analog) and their use as a therapeutic are also disclosed.

24650.P11

Fig. 1

b

1 tGCCTATCTCCCTTGCCAGGGGGCAGAGAAATGATGagGTGAATAGCACTTGCTTGGA
aCGGATAGAGGGAAACGGTCCCCCGTCTTTACTACctcCACTTATCGTGAACGAACCT 60

M M E V N S T C L D -

61 TTGCAGGACACCTGGTACCATACGAACAGAGCAGGATGCACAGGACAGCGCATCTCAGGG
AACGTCCTGTGGACCATGGTATGCTTGTCTCGTCTACGTGTCTGTCGCGTAGAGTCCC 120

C R T P G T I R T E Q D A Q D S A S Q G -

121 ACTCACCTCTGCCCTGGCGGTGGTCTTATATTACCAATTGTTGTGGATGTCTGGGcaa
TGAGTGGAGACGGGACCGCCACCAAGAATAAGTGGTAACAACACCTACAGGACCCGtt 180

L T S A L A V V L I F T I V V D V L G N -

Fig. 1
Continued

181 tatattggcattttgtctgtcctgaggaacaagaagctgcagaatgctggaaatctctt
atataaccagtaaaacagacaggactccttgttcttcacgtcttacgaccttagagaa 240

b I L V I L S V L R N K K L Q N A G N L F -

241 tgggtcagttgtctattgccatCTGGTTGTTGCTGTGTATCCCTATCCGGTCATTCT
acaacagtcaaacagataacggctaGACCAACAACGACACATAGGGATAGGCCAGTAAGA 300

b V V S L S I A D L V V A V Y P Y P V I L -

301 CATACTATTTCAGAACATGGATGGACGCTTGAAATATCCATTGTCAGATCAGTGGCTT
GTATCGATAAAAGGTCTACCTACCTGCACCTTATAGTAACAGTCTAGTCACCGAA 360

b I A I F Q N G W T L G N I H C Q I S G F -

361 CCTGATGGGACTCAGCGTTATTGGATCAGTCTCAACATAACAGCCATAGCTATCACAG
GGACTACCCCTGAGTCGCAATAACCTAGTCAGAAGTTGTATTGTCGGTATCGATAGTTGTC 420

b L M G L S V I G S V F N I T A I A I N R -

421 GTATTGCTACATCTGCCACAGCCTGAGATATGACAAGCTTATAATCAAAGAACCTG
CATAACGATGTAGACGGTGTGGACTCTATACTGTTGAAATATTAGTTCTCGTGGAC 480

b Y C Y I C H S L R Y D K L Y N Q R S T W -

Fig. 1
Continued

481 GTGCTACCTGGCCTGACATGGATACTAACTATAATTGCAATCGTGC_{AA}ACTTTTTGT
CACGATGGAACCGGACTGTACCTATGATTGATATTAAACGTTAGCACGGTTGAAAAAACA 540

b C Y L G L T W I L T I I A I V P N F F V -

541 TGGATCACTACAGTATGACCCCAGGATTTTTCTTGACATTGGCAGACAGTGAGTTTC
ACCTAGTGTGTCATACTGGGTCTAAAAAGAACGTGTAAACGCGTCTGTCACTCAAG 600

b G S L Q Y D P R I F S C T F A Q T V S S -

601 CTCATACACCATAACAGTAGTGGTGGTGCATTTTATAGTCCCTCTTAGTGTGTGACATT
GAGTATGTGGTATTGTCATCACCACCGTAAAATCAGGGAGAATCACAACACTGTAA 660

b S Y T I T V V V V H F I V P L S V V T F -

661 CTGTTACTTAAGAATATGGTTTACTGATCCAAGTCAAACACAGAGTTAGACAAGACTT
GACAATGAATTCTTATACCCAAATCACTAGGTTAGCTCAATCTGTTCTGAA 720

b C Y L R I W V L V I Q V K H R V R Q D F -

Fig. 1
Continued

CAAGCAAAAGTTGACACAAACAGACTTGAGAAATTCTTGACCATGTTGTGGTCTTGT
721 -----+-----+-----+-----+-----+-----+ 780
GTTCGTTTCAACTGTGTTGTCTGAACCTTTAAAGAACTGGTACAAACACCAGAAACA

b K Q K L T Q T D L R N F L T M F V V F V -

ACTTTTGCAGTTGCTGGGCCCTTAAACTTATGGCCTTGCTGTGGCCATTAATCC
781 -----+-----+-----+-----+-----+-----+ 840
TGAAAAACGTCAAACGACCCGGGGAATTGAAATAGCCGGAACGACACCGGTAAATTAGG

b L F A V C W A P L N F I G L A V A I N P -

GTTTCATGTGGCACAAAGATTCCAGAATGGCTGTTGTTAAGCTATTCATGGCCTA
841 -----+-----+-----+-----+-----+-----+ 900
CAAAGTACACCGTGGTTCTAAGGTCTTACCGACAAACAAATTGATAAAAGTACCGGAT

b F H V A P K I P E W L F V L S Y F M A Y -

TTTTAACAGTTGTCATGCTGTTATATATGGTGTGCTAAATCAAAACTTCCGCAAGGA
901 -----+-----+-----+-----+-----+-----+ 960
AAAATTGTCACAGAGTTACGACAATATACCAACACGATTAGTTGAAAGGCGTTCCCT

b F N S C L N A V I Y G V L N Q N F R K E -

Fig. 1
Continued

961 GTACAAAAGAATACTGATGTCCTTATTGACTCCAAGACTGTTGTTCTTGACACATCTAG
CATGTTTCTTATGACTACAGGAATACTGAGGTTCTGACAACAAAGAACTGTGTAGATC 1020

b Y K R I L M S L L T P R L L F L D T S R -

1021 AGGAGGAACTGAGGGATTGAAAAGTAAGCCTCGCCAGCTGTAACCAACAACAATCAAGC
TCCTCCTTGAECTCCCTAACCTTTICATTGGAAAGCGGTGACATTGGTTGTTAGTTCG 1080

b G G T E G L K S K P S P A V T N N N Q A -

1081 AGATATGCTAGGAGAACGAAAGGTCACTGTGGCTGAGCAGGAGAAATGGTGCAGAAATGGT
TCTATACGATCCTCTTCGTTCCAGTGACACCGACTCGTCCCTTTACACGCTTTACCA 1140

b D M L G E A R S L W L S R R N G A K M V -

1141 GATCATCATCAGGCCAAGAAAAGCACAAATTGCAATCATCCATCAAATATTCTGGCCTCA
CTAGTAGTAGTCGGTTCTTTCGTGTTAACGTTAGTAGGTAGTTATAAGACCGGAGT 1200

b I I I R P R K A Q I A I I H Q I F W P Q -

Fig. 1
Continued

1201 GAGTTCATGGCAACATGCCGTCAAGACACAAGATTACCGGAGAAGAAGATGGCTGCCG
-----+-----+-----+-----+-----+
CTCAAGTACCCGTTGTACGGCAGTTCTGTGTTCTAATGCCCTCTCTACCGACGGC

1260

b S S W A T C R Q D T K I T G E E D G C R -

1261 TGAACTGTGCAAGGACGGGATTCCAAAGGTGAGACCCAATGCACTATATCCACATTAT
-----+-----+-----+-----+-----+
ACTTGACACGTTCCCTGCCCTAAAGGGTTCCACTCTGGGTTACGTGATATAGGTGTAATA

1320

b E L C K D G I S Q R * SEQ ID NO:2

Fig. 2

GGGAGCTCGACGCTCTGGGATCCACCGGCGCCGGCCCTGCCAGCGCGATGGCGGGCGG
1 +-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
CCCTCGAGCTGCGAGACCCCTAGGTGGCCGGCCGGACGGTCGCGCTACCGCCCCGCC
a M A G R -

CTGTGGGCTCGCCGGCGGGACCCCCAAGGGAACGGCAGCAGCGCGCTGCTCAACGTC
61 +-----+-----+-----+-----+-----+-----+-----+-----+-----+ 120
GACACCCCGAGCGGGCCGCCCTGGGGTTCCCGTTGCCGTCGCGCGACGAGTTGCAG
a L W G S P G G T P K G N G S S A L L N V -

TGGCAGGCGGCGCCGGCGCCGGGACGGTGTGCGGCCGCCCTCGTGGCTGGCGCC
121 +-----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
AGCGTCCGCCGCCGGCCGCGGCCCTGCCACACGCCGGCGCCGGAGCACCGACCAGGGCG
a S O A A P G A G D G V R P R P S W L A A -

Fig. 2
Continued

181 ACCCTGGCTCCATCCTCATCTCACCATCGTGGTGGACATCGTGGGAAACCTCCTGGTG
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
TGGGAGCGGAGGTAGGAGTAGAAGTGGTAGCACCACTGTAGCACCCGTTGGAGGACCAC

a T L A S I L T F T I V V D I V G N L L V -

241 GTCCTGTCCGTGTATCGGAACAAGAAGCTGAGGAACGCAGGAAATGTGTTGTGGTGAGC
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
CAGGACAGGCACATAGCCTTGTCTTCGACTCCTTGCCTACACAAACACCACCTCG

a V L S V Y R N K K L R N A G N V F V V S -

301 CTGGCAGTTGCAGACCTGCTGGTGGCCGTGTATCCGTACCCCTGGCGCTGGCGTCTATA
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
GACCGTCAACGTCTGGACGACCACCGGACATAGGCATGGGAACCGCGACCGCAGATAT

a L A V A D L L V A V Y P Y P L A L A S I -

361 GTTAACAATGGGTGGAGCCTGAGCTCCCTGCATTGCCAACTTAGTGGCTCCTGATGGC
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
CAATTGTTACCCACCTCGGACTCGAGGGACGTAACGGTTGAATCACCGAAGGACTACCCG

a V N N G W S L S S L H C Q L S G F L M G -

Fig. 2
Continued

TTGAGCGTCATGGGTCCGTTTCAGCATCACGGATTGCCATCAACCGCTATTGCTGC
421 -----+-----+-----+-----+-----+-----+-----+-----+ 480
AACTCGCAGTAGCCCAGGCAAAGTCGTAGTGCCTAACGGTAGTTGGCGATAACGACG

a L S V I G S V F S I T G I A I N R Y C C -

ATCTGCCACAGCCTCAGATAACGCAAGCTGTATAGCGCACGAATTCCCTCTGCTACGTG
481 -----+-----+-----+-----+-----+-----+-----+-----+ 540
TAGACGGTGTGGAGTCTATGCCGTTGACATATGCCGTGCTTAAGGGAGACGATGCAC

a I C H S L R Y G K L Y S G T N S L C Y V -

TTCCTGATCTGGACGCTGACGCTCGTGGCATCGTGCCAACCTGTGTGGGGACCTG
541 -----+-----+-----+-----+-----+-----+-----+-----+ 600
AAGGACTAGACCTGCGACTGCGAGCACCGCTAGCACGGTTGGACACACACCCCTGGGAC

a F L I W T L T L V A I V P N L C V G T L -

CAGTACGACCCGAGGATCTATTCTGTACCTTCACGCAGTCAGCTCAGCCTACACG
601 -----+-----+-----+-----+-----+-----+-----+-----+ 660
GTCAATGCTGGCTCCTAGATAAGGACATGGAAGTGCCTCAGGCAGTCAGTCGGATGTGC

a Q Y D P R I Y S C T F T O S V S S A Y T -

Fig. 2
Continued

661 ATCGCCGTGGTGGTGTCCATTCAAGTTCCGATGCTCGTAGTCGTCTCTGTTACCTG
661 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 720
TAGGGCACCACCAAGGTAAAGTATCAAGGCTACGAGCATCAGCAGAAGACAATGGAC

a I A V V V F H F I V P M L V V V F C Y L -

721 AGAACATGGGCCCTGGTCTTCAGGTCAAGATGGAAGGTGAAACCGGACAACAAACCGAAA
721 -----+-----+-----+-----+-----+-----+-----+-----+ 780
TCTTAGACCCGGGACCAAGAAGTCCAGTCTACCTCCACTTGGCCTGTTGGCTTT

a R I W A L V L Q V R W K V K P D N K P K -

781 CTGAAGCCCCAGGACTTCAGGAATTTCAGTCACCATGTTGTGGTTTGTCCTCTTGCC
781 -----+-----+-----+-----+-----+-----+-----+-----+ 840
GACTTCGGGGCTCTGAAGTCCTAAACAGTGGTACAAACACCAAAACAGGAGAACGG

a L K P Q D F R N F V T M F V V F V L F A -

841 ATTTGCTGGGCTCCTCTGAACCTCATGGTCTCGTTGTGGCCTCGAACCCGCCAGCATG
841 -----+-----+-----+-----+-----+-----+-----+-----+ 900
TAAACGACCCGAGGAGACTTGAAGTAACCAGAGCAACACCGGAGCCTGGGCGGTGTCAC

a I C W A P L N F I G L V V A S D P A S M -

Fig. 2
Continued

GCACCCAGGATCCCCGAGTGGCTGTTGTGGCTAGTTACTATATGGCATATTCACAGC
901 -----+-----+-----+-----+-----+-----+ 960
CGTGGGTCTAGGGCTACCGACAAACACCGATCAATGATATAACGTATAAAGTTGTCG

a A P R I P E W L F V A S Y Y M A Y F N S -

TGCCTCAATGCGATCATATGGACTACTGAACCAAAATTTCAGGCAGGAATACAGAAAA
961 -----+-----+-----+-----+-----+-----+ 1020
ACGGAGTTACGCTAGTATACCTGATGACTGGTTAAAGTCCGTCTTATGTCTTTT

a C L N A I I Y G L L N Q N F R Q E Y R K -

ATTATAGTCTCATTGTGTACCACCAAGATGTTCTTGTGGATAGCTCCAATCATGTAGCA
1021 -----+-----+-----+-----+-----+-----+ 1080
TAATATCAGAGTAACACATGGTGGTTCTACAAGAACACCTATCGAGGTTAGTACATCGT

a I I V S L C T T K M F F V D S S N H V A -

GATAGAATTAAACGCAAACCCCTCTCCATTAATAGCCAACCATAACCTAATAAAGGTGGAC
1081 -----+-----+-----+-----+-----+-----+ 1140
CTATCTTAATTGCGTTGGGAGAGGTAATTATCGGTTGGTATTGGATTATTCACCTG

a D R I K R K P S P L I A N H N L I K V D -

TCCGTTAA SEQ ID NO:3
1141 ----- 1149
AGGCAAATT

a S V * - SEQ ID NO:4

Fig. 3

ATGAAGGGCAATGTCAAGCAGCTGCTCAATCCCACTCAGCAGGCTCCAGGCAGGGAG
1 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 60
TACTTCCCGTTACAGTCGCTCGACGAGTTACGGTGAGTCGTCCAGGTCCGCCGCCCTC

a M K G N V S E L L N A T Q Q A P G G G E -

GGAGCGAGACCACGACCGTCTGGATGCCCTCTACACTGGCCTCATCCTCATCTTAC
61 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 120
CCTCCCTCTGGTGGCTGGCAGGACCTACCCGAGATGTGACCGGAAGTAGGAGTAGAAATGG

G G R P R P S W M A S T L A F I L I F T -

ATCGTGGTGGACAATTCTGGGAAACCTGCTGGTCACTCTGTCTGTGTACCCGAAAGAAG
121 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
TAGCACCAACCTGTAAGACCCGGTGGACGACAGTAGGACAGACACATGGCCTTGTCTTC

I V V D I L G N L L V I L S V Y R N K K -

CTCACGAACTCAGGGAAATATAATTGTGGTGAGTTAGCTGTGGCAGACCTCGTGGTGGCT
181 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 240
GAGTCCTTGAGTCCCTATATAAACACCACTCAAATCGACACCGTCTGGAGCACCACCGA

a L R N S G N I F V V S L A V A D L V V A -

Fig. 3
Continued

241 CTTTACCCCTATCCCTGGTGTGACATCTATCCTAACAAACGGATCGAATCTGGGATAT 300
CAAATGGGAATAGGCAACCACGACTGTAGATAGGAATTGTTGCCTACCTAGACCCATA
a V Y P Y P L V L T S I L N N G W N L G Y -

301 CTACACIGTCAACTCAGGCCATTCTAATGGGCTTGACTGTCATCGGCTCGATATTGAAC 360
GAATGTGACAGTTCAAGTCGGTAAAGATTAACCGAACTCACAGTAGCCGACCTATAACTTG
a L H C Q V S A F L M G L S V I G S I L N -

361 ATCACGGGGATCGCTATGAACCGTTACTGCTACATTGCCACAGCCTCAAGTACGACAAA 420
TAGTCCCCCTAGCGATACTTGGCAATGACCATGTAACGGTGTGGAGTTCATGCTT
a T T G I A M N R Y C Y I C H S L K Y D K -

421 ATATACAGTAACAAGAACTCCCTCTGCTACGTGTTCCCTCATATGGATGCTGACACTCATC 480
TATATGTCATTGTTCTTGACCCGAGACGATGCCACAAGGACTATACTACCACTGTGAGTAG
a T Y S N K N S L C Y V F L I W M L T L I -

481 GCCATCATGCCAACCTGCAAACCGGAACACTCCAGTACCGATCCCCGGATCTACTCCTGT 540
CGGTAGTACGGGTTCGACGTTGGCCTTGTGAGGTATGCTAGGGCCCTAGATGACCGACA
a A I M P N L Q T G T L Q Y D P R I Y S C -

Fig. 3
Continued

541 ACCTTCACCCAGTCTGTCAGCTCAGGGTACACGATAGCAGTGGTGGTTTCATTTCATC
TGGAAAGTGGGTCAAGACAGTCGAGTCGCATGTGCTATCGTCACCACCAAAACGTAAGTAG 600

a T F T Q S V S S A Y T I A V V V F H F I -

601 GTGCCTATGATTATTGTCATCTTCTGCTACTTAAGGATATGGGTCTGGTCCTTCAGGTC
CACGGATACTAATAACAGTAGAAGACGATCAATTCTATACCCAGGACCAAGGAAGTCCAG 660

a V P M I I V I F C Y L R I W V L V L Q V -

661 AGACGGAGGGTGAAACCCGACAACAAGCCAACTGAAGCCCCAGGACTTCAGGAACTT
TCTGCCTCCCACTTGGCTGTTGTTGGGTTGACTTCGGGGTCTGAAGTCCTTGAAA 720

R R R V K P D N K P K L K P Q D F R N F -

721 GTCACCAATGTTCTGAGTTTGTACTTTGCCATTGTTGGGCCCCACTCAACCTCATA
CACTGGTACAAGCATCAAAACATGAAAAACGGTAAACAACCCGGGTCAAGTTGGAGTAT 780

a V T M F V V F V L F A I C W A P L N L I -

Fig. 3
Continued

781 GGTCTTATTGTCCCCCTCAGACCCCTGCCACCATGGTCCCCAGGATCCCAGAGTGGCTGGTC
CCAGAAATAACACCGGAGTCTGGGACCGTGGTACCAAGGGTCTAGGGTCTCACCGACAAG 840

a G L I V A S D P A T M V P R I P E W L F -

841 GTGGCTAGTTACTACCTGGCGTACTTCACAGCTCCCTAACGCAATTATATAACGGACTA
CACCGATCAATGATGGACCGCATGAAGTTGTCGACGGAGTTGGCTTAATATATGCCTGAT 900

a V A S Y Y L A Y P N S C L N A I I Y G L -

901 CTGAATCAGAATTTCAGAAAGGAATACAAAAAGATTATTGTCTCGTTGTGCACACCCAAG
GACTTAGCTTAAAGTCTTCCTTATGTTTTCTAATAACAGAGCAACACGTGTCGGTTTC 960

a L N Q N F R K E Y K K I I V S L C T A K -

961 ATGTTCTTGTGGAGAGTTCAAATGAAGCAGATAAGATTAAATGTAAGCCCTCTCCA
TACAAGAAACACCTCTCAAGTTACTTCTTCGTCTATTCTAATTACATTGGGAGAGGT 1020

a M F F V E S S N E E A D K I K C K P S P -

Fig. 3
Continued

1021 CTAATACCAATAATAACTCCTCCCGTGGACTCTGTTAA
-----+-----+-----+-----+
GATTATGGGTTATTATTGAAGGAGGGCACCTGAGACAAATT

a L I P N N N F L P V D S V * (SEQ ID NO:14)

Fig. 4

ggaaacatcttgtggtagcgtggcagacctggtggtggccatttatccgtac
1 -----+-----+-----+-----+-----+-----+-----+ 60
ccttgtagaaacaccactcgaaatgccaccgtctggaccaccaccgtaaataggcatg

a G N I F V V S L A V A D L V V A I Y P Y -

ccgttgggtctgtcgatattaaacaacgggtggAACCTGGCTATCTGACTGCCAA
61 -----+-----+-----+-----+-----+-----+-----+ 120
ggcaaccacgactacagctataattgttgcacccatggaccggatagacgtgacggtt

a P L V L M S I F N N G W N L G Y L H C Q -
-
-

gtcagtgggtcctgtatggcctgagcgtcatcggtccatattcaacatcacggcattc
121 -----+-----+-----+-----+-----+-----+-----+ 180
cagtccccaggactaccggactcgcagtagccgaggataagttgttagtggccgttag

a V S G F L M G L S V I G S I F N I T G I -
-
-

gccatcaaccgctacTGTACATCTGCCACAGTCTCAAGTGCGACAAACTGTACAGCAGC
181 -----+-----+-----+-----+-----+-----+-----+ 240
cgtagttggcgatgACAATGTAGACGGTGTCAAGTTACGCTGTTGACATGTCGTCG

a A I N R Y C Y I C H S L K C D K L Y S S -

Fig. 4
Continued

241 AAGAACTCCCTCTGCTACGTGCTCCTCATATGGCTCCTGACGGCGGCCGTCCTGCCAAC + 300
 TTCTTGAGGGAGACGATGCACGAGGAGTATACCGAGGACTGCCGCCAGGACGGGTTG

a K N S L C Y V L L I W L L T A A V L P N -

301 CTCCGTCGTGGACTCTCCAGTACGAGCCGAGGATCTACTCGTGCACCTTCGCCAGTCC + 360
 GAGGCAGCACCTGAGAGGTATGCTCGCTCCTAGATGAGCACGTGGAAGCGGGTCAGG

a L R R G T L Q Y E P R I Y S C T F A O S -

361 GTCAGCTCCGCCTACACCATGCCGTGGTGGTTTCACITTCCTCGTCCCCATGATCATA + 420
 CAGTCGAGGCGGATGTGGTAGCGGCACCACCAAAAGGTGAAGGAGCAGGGTACTAGTAT

a V S S A Y T I A V V V F H F L V P M I I -

421 GTCATCTTCTGTTACCTGAGAATATGGATCCTGGTTCTCCAGGTCAAGACAGAGGGTGAAA + 480
 CAGTAGAAGACAATGGACTCTTATACTAGGACCAAGAGGTCCAGTCTGTCTCCACTTT

a V I F C Y L R I W I L V L Q V R Q R V K -

Fig. 4
Continued

481 CCTGACCGCAAACCCAAACTGAAACCACACGACTTCAGGAATTGTCAACCATGTTGTG
GGACTGGCGTGTGGTTGACTTGGTGTGCTGAAGTCCTAAAACAGTGGTACAAACAC 540

a P D R K P K L K P H D F R N F V T M F V -

541 GTTTTGTCCTTTTGCCATTGCTGGCTCCTCTGAACCTCATGGCCTGGCCGTGGCC
CAAAAACAGGAAAAACGGTAAACGACCCGAGGAGACTTGAAGTAACCGGACCGGCACCGG 600

a V F V L F A I C W A P L N F I G L A V A -

601 TCTGACCCGCCAGCATGGTGCCTAGGATCCCAGAGTGGCTGTTGTGGCCAGTTACTAC
AGACTGGGGCGGTGTAACACGGATCCTAGGGTCTCACCGACAAACACCGGTCAATGATG 660

a S D P A S M V P R I P E W L F V A S Y Y -

661 ATGGCGTATTCAACAGCTGCCATTATGCCATTATATCGGGCTACTGGAACCAAAATTTC
TACCGCATAAAGTTGTCACGGAGTACGTAATATAGCCGATGACCTTGGTTAAAG 720

a M A Y F N S C L N A I I S G Y W N Q N F -

Fig. 4
Continued

AGGAAGGAATAACAGGAGAATTATAGTCTCGCTCGTGACAGCCAGGGTGTCTTGTGGAC
721 -----+-----+-----+-----+-----+-----+ 780
TCCTTCCTTATGTCCTCTTAATATCAGAGCGAGCACTGTCGGTCCCACAAGAACACCTG

a R K E Y R R I I V S L V T A R V F F V D -

AGCTCTAACGACGTGGCCGATAGGGTTAAATGGAAACCGTCTCCACTGATGACCAACAAT
781 -----+-----+-----+-----+-----+-----+ 840
TCGAGATTGCTGCACCGGCTATCCCAATTACCTTGGCAGAGGTGACTACTGGTTGTTA

a S S N D V A D R V K W K P S P L M T N N -

AATGTAGTAAAGGTGGACTCCGTTAA SEQ ID NO:5
841 -----+-----+----- 867
TTACATCATTTCCACCTGAGGCAAATT

a N V V K V D S V * - SEQ ID NO:6

Fig. 5

C

M Q G N G S A L P N -

1 ATGGCCCTGC~~GGG~~GGGACGCCAACAGGGACCATQCAGGGCAACGGCAGCGCGCTGCCA
TACCGGGACGCC~~GGG~~CCCTGCGCTTGTCCTGGTACGTCCC~~GTT~~GCCGT~~CGCG~~ACGGGT 60

61 ACGCCTCCCAG~~CCC~~GTGCTCCGCGGGACGGCGCGGCCCTCGTGGCTGGCGTCCGCC
TGC~~GG~~AGGGT~~CGGG~~ACGAGGCGCCCTGCGCGGCCGGAGCACCGACCGCAGGCGGG 120

A S Q P V L R G D G A R P S W L A S A L -

121 TAGCCTGCGTCCTCATCTTACCATCGTGGTGGACATCCTGGCAACCTCCTGGTCATCC
ATCGGACGCAGGGAGTAGAAGTGGTAGCACCACCTGTAGGACCC~~GTT~~GGAGGACCAGTAGG 180

C

A C V L I F T I V V D I L G N L L V I L -

Fig. 5
Continued

181 TGTCCGTGTATCGGAACAAGAAGCTCAGGAACGCAggaaacatctttgtggtgagcttag
ACAGCCACATAGCCTTGTCTTCAGTCCTTGGTccctttagaaaacaccactcgaatc 240

c S V Y R N K K L R N A G N I F V V S L A -

241 cggtggcagacctgggtggccatttatccgtacccgttggtgctgatgtcgatattta
gcacccgtctggaccaccacccgtaaataggcatggcaaccacgactacagctataaat 300

c V A D L V V A I Y P Y P L V L M S I F N -

301 acaacgggtgaaacctggctatctgactgccaagtcagtgggttcctgatggcctga
tgttgcacccatggaccgcatacgtgacggttcagtcacccaaggactacccggact 360

c N G W N L G Y L H C Q V S G F L M G L S -

361 gcgtcatcggtccatattcaacatcacggcatgccatcaaccgtactTGCTACATCT
cgcagttagccgaggataagtgttagtgccgtagcggtagttggcgatgACGATGTAGA 420

c V I G S I F N I T G I A I N R Y C Y I C -

421 GCCACAGTCTCAAGTACGACAAACTGTACAGCAGCAAGAACCTCCCTTGCTACGTGCTCC
CGGTGTCAGAGTTCATGCTGTTGACATGTCGTTCTGAGGGAGACGATGCCACGAGG 480

c H S L K Y D K L Y S S K N S L C Y V L L -

Fig. 5
Continued

481 TCATATGGCTCCTGACGCTGGCGGCCGTCCCTGCCAACCTCCGTGCAGGGACTCTCCAGT 540
AGTATAACCGAGGACTGGACCGCCGGCAGGAACGGGTTGGAGGCACGTCCCTGAGAGGTCA

C I W L L T L A A V L P N L R A G T L Q Y -

541 ACGACCCGAGGATCTACTCGTGCACCTTCGCCAGTCCGTCAAGCTCCGCCTACACCATCG 600
TGCTGGGCTCCTAGATGAGCACGTGGAAGCGGGTCAGGCAGTCGAGGCGGATGTGGTAGC

D P R I Y S C T F A Q S V S S A Y T I A -

601 CCGTGGTGGTTTICCACTTCCTCGTCCCCATGATCATAGTCATCTCTGTTACCTGAGAA 660
GGCACCAACAAAAGGTGAAGGAGCAGGGTACTAGTATCAGTAGAAGACAATGGACTCTT

C V V V F H F L V P M I I V I F C Y L R I -

661 TATGGATCCTGGTTCTCCAGGTCAAGACAGAGGGTGAACCTGACCGCAAACCAAACGTGA 720
ATACCTAGGACCAAGAGGTCCAGTCTGTCTCCACTTGGACTGGCGTTGGGTTGACT

C W I L V L Q V R Q R V K P D R K P K L K -

Fig. 5
Continued

AACCACAGGACTTCAGGAATTGTCAACATGTTGTGGTTTGTCTCTTGCCATT
721 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 780
TTGGTGTCTGAAGTCCTTAAACAGTGGTACAAACACCAAAACAGGAGAACGGTAAA

C P Q D F R N F V T M F V V F V L F A I C -

GCTGGGCTCCTCTGAACCTTCATTGGCCTGGCGTGGCCTCTGACCCGCCAGCATGGTGC
781 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 840
CGACCCGAGGAGACTTGAAGTAACCGGACCGGACCGGAGACTGGGGCGTACCG
W A P L N F I G L A V A S D P A S M V P -

CTAGGATCCCAGAGTGGCTGTTGTGGCAGTTACTACATGGGTATTCAACAGCTGCC
841 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 900
GATCCTAGGGTCTCACCGACAAACACCGGTCAATGATGTACCGATAAAGTTGTCGACGG

C R I P E W L F V A S Y Y M A Y F N S C L -

TCAATGCCATTATACGGCTACTGAACCAAATTCAAGGAAGGAATACAGGAGAATTA
901 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 960
AGTTACGGTAATATATGCCCGATGACTGGTTAAAGTCCTCCTATGTCCTCTTAAT

C N A I I Y G L L N Q N F R K E Y R R I I -

Fig. 5
Continued

361 TAGTCTCGCTCTGTACAGCCAGGGTGTCTTGTGGACAGCTCTAACGACGTGGCCGATA
ATCAGAGCGAGACATGTCGGTCCCACAAGAAACACCTGTCGAGATTGCTGCACCGGCTAT 1020

C V S L C T A R V F F V D S S N D V A D R -

1021 GGGTTAAATGGAAACCGTCTCCACTGATGACCAACAATAATGTAGTAAAGGTGGACTCCG
CCCAATTACCTTGGCAGAGGTGACTACTGGTTATTACATCATTTCCACCTGAGGC 1080

V K W K P S P L M T N N N V V K V D S V - (SEQ ID NO:12)

1081 **TTTAA** ----- 1085 (SEQ ID NO:11)
AAATT

* -

Fig. 6

GGAGAGTCTCGATGTCAGAGAACGGCTCCTGCCAACTGCTGCGAGGC
1 -----+-----+-----+-----+-----+-----+ 60
CCTCTCAGACGCTACAGTCTCTGCCGAGGAAGCGTTGACGACGCTCCGCC
a M S E N G S F A N C C E A G G W -

GCAGTGCGCCGGCTGGTCGGGGCTGGCAGCGCGCCCTCCAGGACCCCTCGACCT
61 -----+-----+-----+-----+-----+-----+ 120
CGTCACGCCGGCCCCGACCAGCCCCCGACCGTCGCCGCCGGAGGTCTGGGAGCTGGA
a A V R P G W S G A G S A R P S R T P R P -

CCCTGGGTGGCTCCAGCGCTGTCCGCCGTGCTCATCGTCACCACCGCCGTGGACGTCGTG
121 -----+-----+-----+-----+-----+-----+ 180
GGGACCCACCGAGGTGGCGACAGGCGCCACGAGTAGCAGTGGTGGCGCACCTGCAGCAC
a P W V A P A L S A V L I V T T A V D V V -

Fig. 6
Continued

181 GGCACACCTCCCTGGT GATCTCTCTCGT GCTCAGGAACCGCAAGCTCCGGAACGCAGGTAAT 240
 CCGTTGGAGGACC ACTAGGAGAGGGAC CGAGTCCTTGGCGTTGAGGCCTTGCGTCCATT A

a G N L L V I L S V L R N R K L R N A G N -

241 TTGTTCTTGGTGAGTCTGGCATTGGCTGACCTGGTGGTGGCCTTCTACCCCTACCCGCTA 300
 AACAAAGAACCACTCAGACCGTAACCGACTGGACCACCACCGGAAGATGGGGATGGGCAT

a L F L V S L A L A D L V V A F Y P Y P L -

301 ATCCTCGTGGCCATCTCTATGACGGCTGGGCCCTGGGGAGGAGCACTGCAAGGCCAGC 360
 TAGGAGCACCGTAGAAGATACTGCCGACCCGGGACCCCCTCCTCGT GACGTTCCGGTCG

a I L V A I F Y D G W A L G E E H C K A S -

361 GCCTTTGTGATGGGCCTGAGCGTCATCGGCTCTGCTTCAATATCACTGCCATGCCATT 420
 CGGAAACACTACCCGACTCGCAGTAGCCGAGACAGAAGTTATAGTGACGGTAGCGTAA

a A F V M G L S V I G S V F N I T A I A I -

421 AACCGCTACTGCTACATCTGCCACAGCATGGCCTACCAACCGAATCTACCGGGCTGCCAC 480
 TTGGCGATGACGATGTAGACGGTGTCTGACGGATGGTGGCTTAGATGGCCCGACCGTG

a N R Y C Y I C H S M A Y H R I Y R R W H -

Fig. 6
Continued

ACCCCTCTGCACATCTGCCTCATCTGGCTCCTCACCGTGGTGGCCTTGCTGCCCAACTTC
 481 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 540
 TGGGGAGACGTGTAGACGGAGTAGACCGAGGAGTGGCACCACCGAACGACGGGTTGAAG
 a T P L H I C L I W L L T V V A L L P N F -

 TTTGTGGGTCCCTGGAGTACGACCCACGCATCTATTCCCTGCACCTTCATCCAGACCGCC
 541 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 600
 AACACCCCCAGGGACCTCATGCTGGGTGGTAGATAAGGACGTGGAAGTAGGTCTGGCGG
 F V G S L E Y D P R I Y S C T F I Q T A -

 AGCACCCAGTACACGGCGGCAGTGGTGGTCATCCACTTCCTCCCTATCGCTGTCGTG
 601 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 660
 TCGTGGGTATGTGCCGCCGTACCAACCACTAGGTGAAGGAGGAGGGATAGCGACAGCAC
 S T Q Y T A A V V V I H F L L P I A V V -

 TCCTTCTGCTACCTGCGCATCTGGGTGCTGGTGCCTCAGGCCCGCAGGAAAGCCAAGCCA
 661 -----+-----+-----+-----+-----+-----+-----+-----+-----+ 720
 AGGAAGACGATGGACGCGTAGACCCACGACCACGAAGTCCGGCGTCCTTCGGTTCGGT
 a S F C Y L R I W V L V L Q A R R K A K P -

Fig. 6
Continued

721 GAGAGCAGGCTGTGCCTGAAGCCCAGCGACTTGGAGCTTCTAACCATGTTGTGGTG
CTCTCGTCCGACACGGACTTCGGGTCGCTGAACGCCCTCGAAAGATTGGTACAAACACCAC 780

a E S R L C L K P S D L R S F L T M F V V -

781 TTTGTGATCTTGCCATCTGCTGGGCTCCACTTAACACTGCATGGCCTCGCTGTGGCCATC
AAACACTAGAAACGGTAGACGACCCGAGGTGAATTGACGTAGCCGGAGCGACACCGGTAG 840

F V I F A I C W A P L N C I G L A V A I -

841 AACCCCCAAGAAATGGCTCCCCAGATCCCTGAGGGCTATTTGTCACTAGCTACTTACTG
TTGGGGGTTCTTACCGAGGGTCTAGGGACTCCCCGATAAACAGTGATCGATGAATGAC 900

a N P Q E M A P Q I P E G L F V T S Y L L -

901 GCTTATTCAACAGCTGCCTGAATGCCATTGTCTATgggCTCTTGAACCAAAACTTCCGC
CGAATAAGTTGTCGACGGACTTACGGTAACAGATAcccgAGAACTGGTTGAAGGCG 960

a A Y F N S C L N A I V Y G L L N Q N F R -

Fig. 6
Continued

961 AGGGAAATACAAGAGGATCCTCTTGGCCCTTGGAACCCACGGCACTGCATTCAAGATGCT
TCCCTTATGTTCTCCTAGGAGAACGGGAAACCTTGGGTGCCGTGACGTAAGTTCTACGA 1020

a R E Y K R I L L A L W N P R H C I Q D A -

1021 TCCAAGGGCAGCCACGGGAGGGCTGCAGAGCCCAGCTCCACCCATCATTGGTGTGCAG
AGGTTCCCGTCGGTGCCTCCCCACGTCTCGGGTCGAGGTGGTAGTAACCACACGTC 1080

S K G S H A E G L Q S P A P P I I G V Q -

1081 CACCAGGCAGATGCTCTCTAGCCTG (SEQ ID NO:15)
1105 GTGGTCCGTCTACGAGAGATCGGAC

H Q A D A L * (SEQ ID NO:16)

Fig. 7

xmr	MMEVNSTCLDCRTPGTIRTEQDAQDSASQG.....LT
ov	MAGRlwGSPGGTPKGNGSSALLNVSAAPGAGDGVRPRPSWLA
I	
xmr	SALAVVLIFTIVVDVLGNILVILSVLRNKKLQNAGNLFVVLSIADLVVAVYPYVILI
ov	ATLASILIFTIVVDIVGNLLVVLSVYRNKKLRNAGNFVVSLAVADLLVAVYPYPLALA
hum	GNIFVVSLAVADLVVAIYPYPLVLM
II	
III	
xmr	AIFQONGWTLGNIHCQISGFLMGLSVIGSVFNITAIAINRYCYICHSLRYDKLYNQRSTW
ov	SIVNNNGWSLSSLHQCQISGFLMGLSVIGSVFSITGIAINRYCCICHSLRYGKLYSGTNSL
hum	SIFNNNGWNLGYLHCQVSGFLMGLSVIGSIFNITGIAINRYCYICHSLCDKLYSSKNSL
IV	
xmr	CYLGTLWILTIIIAIVPNFFVGSLQYDPRIFSCFAQTVSSSYTITVVVVVFHVIPVLSVVT
ov	CYVFLIWLTLLVAIVPNLCVGTQYDPRISCTFTQSVSAYTIAVVVFHFHVIPMLVVV
hum	CYVLLIWLLTA.AVLPNLRRGTQYEPRISCTFAQSVSSAYTIAVVVFHFHVPMIIIVI
V	
VI	
xmr	FCYLRIWVLVIQVKHRVRQDFKQKLTTQDLRNFTTMFVVFVLFAVCWAPLNFIGLAVAII
ov	FCYLRIWALVLQVRWKVPDNKPQLKPQDFRNFVTMFVVFVLFAICWAPLNFIGLVVAS
hum	FCYLRIWILVLQVRQRVKPDRPKLKPQDFRNFVTMFVVFVLFAICWAPLNFIGLAVAS
VII	
xmr	NPFHVAPKIPEWLFVLSYFMAYFNSCLNAVIYGVLNQNFRKEYKRILMSLLPRLLFLD
ov	DPASMAPRIPEWLFVASYYMAYFNSCLNAIIYGLLNQNFRQEYRKIVSLCTTKMFFVVD
hum	DPASMVPRIPEWLFVASYYMAYFNSCLNAIIISGYWNQNFRKEYRRIIVSLVTARVFFVVD
*	
xmr	TSRGGTEGLKSXPSPAVTNNNQADMGEARSLWLSSRRNGAKMVIIIRPRKAQIAIIHQIF
ov	SSNHVADRIKRKPSPPLIANHNLIKVDSV* SEQ ID NO:4
hum	SSNDVARDVKWKPSPLMTNNNKKVDSV* SEQ ID NO:6
*	
xmr	WPQSSWATCRQDTKITGEEDGCRELCKDGISQR
	SEQ ID NO:2

Fig. 8

	I		
Sheep	MAGRLWGS P GGTPKGNC G GALLNVSQAAPGAGDGVRPRPSWLAATLASILIFTIVVDIVGNLLV L SVYRNKKL R NAGN		
Human	MQGNGS A LPNASQPVLRGDCA...RPSWLASALACVLIFTIVVDIVGNLLV L SVYRNKKL R NAGN	5	
Xenopus	MMEVN N STC I CRT P GTIRTEQDAQDSASQG.....LTSALAVLIFTIVVDV L GNILV L SVLRNKKL Q NAGN	5	
Consensus	-----L---L---LIFTIVVD--GN-LV-LSV-RNKKL-NAGN		
	II	III	
Sheep	/FVVSLAVADLLVAVV/PYPLALASTIVNNCGWSLSSLHCOLSGFLMGLSVIGSVESITGIAINRYCCICICHSLRYKLYSGT	15	
Human	/FVVSLAVADLVVAAVYPPVPLVMSIFNNCGWLGYLHCQVSGFLMGLSVIGSIFNITGIAINRYCYICHSLKYDKLYSSK	14	
Xenopus	/FVVSLSIADLVVAVVYPPVILIAIFQNGWTLCNIHCQISGFLMGLSVIGSVFNITAI A INRYCYICHSLRYDKLYNQR	14	
Consensus	-FVVSL--ADL-VA-YPP--L--I--NGW-L---HCQ-SGFLMGLSVIGS-F-IT-IAINRYC-ICHSL-Y-KLY---		
	IV	V	
Sheep	NSLCIVFLINTLTLVAIVPNLC/GTLQYDPRISCTFTQS V SAYTI A VVVFH F IVPMLVVVFCYLR I WLV L QVRWKV	231	
Human	NSLCIV V LLW L TLAALV P NLRAGT L QYDPRISCTFAQS V SAYTI A VVVFH F IVPMLIV I FCYLR I WLV L QVRQRV	221	
Xenopus	STWCYLG L TW L TC I IAV V PNFFVG S QYDPRISCTFAQT V SSSYTITVVVVFH F IVP L SV V FCYLR I WLV V IQVKHRV	225	
Consensus	--CY--L-W-LT--A--PN---G-LQYDPR I -SCTF-Q-VSS-YTI-VVV-HF-VP---V-FCYLR I W-LV-QV---V		
	VI	VII	
Sheep	KPDNKPKLK P QDFRN F TMFVV V FVLF A ICWAPLNFIGL V ASDPASMAPRIPEWLFV A SY Y MA Y FNSCLNAI I YGLLNQ	316	
Human	KPDRKPKLK P QDFRN F TMFVV V FVLF A ICWAPLNFIGLAVASDPASMAPRIPEWLFV A SY Y MA Y FNSCLNAI I YGLLNQ	300	
Xenopus	RQDFKQKL T QD L RNF L TMFVV V FVLF A ICWAPLNFIGLAVAINPFHV A PKIPEWLFV L SY F MA Y FNSCLNAV I YGLLNQ	305	
Consensus	--D-K-KL-P-D-PNF-TMFVV V FVLF A -CWAPLNFIGL-VA--P----P-IP E WLFV-SY-MA Y FNSCLNA- I Y G -LNQ		
Sheep	NFRQSYRKII V SLCTTKMFFDSSNHVADRIKRKPSP L IANHN L IKVDSV 366 (SEQ ID NO:4)		
Human	NFRKEYRR I V SLCTARVFFDSSNDVADRV K WPSP L M T NNNNV V KDSV 350 (SEQ ID NO:12)		
Xenopus	NFRKEYKR I ILMS L TPR L FLDT S RG G TE G L K SKPS P AV T NNNQADM L GEAR S L W S R RNGAKM V II R PRKAQ I AI H 334		
Consensus	NFR-EY--I--SL-T----F-D-S-----KPSP---N-N-----		
Xenopus	QIFWPQSSWATCRQDTKITGEEDGC R ELCKDG I QR 420 (SEQ ID NO:2)		

Fig. 9




Fig. 10a




Fig. 10b




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16






Fig. 17

Histology

^{125}I -MEL Binding

mRNA



17a




17b



17c

Fig. 18

18a



18b

Human 1b	KSEN <u>G</u> SFAN <u>C</u> CEAGGWA <u>R</u> P <u>G</u> WS <u>G</u> AS <u>P</u> SR <u>T</u> PR <u>P</u> W <u>A</u> P <u>L</u> S <u>A</u> V <u>I</u> L <u>T</u> V <u>D</u> V <u>G</u> N <u>L</u> L <u>V</u> I <u>L</u> S <u>V</u> L <u>R</u> N <u>R</u> K <u>L</u> R <u>N</u> A <u>G</u> N <u>L</u> F <u>L</u> V <u>S</u> L <u>A</u> L <u>A</u> D <u>L</u> L <u>V</u> A <u>F</u> <u>P</u> <u>Y</u> <u>P</u> <u>L</u> I <u>V</u> A <u>I</u> F <u>Y</u> <u>D</u> G <u>W</u> L	
Human 1a	M <u>Q</u> G <u>N</u> S <u>A</u> L <u>P</u> N <u>A</u> S <u>Q</u> P <u>V</u> R <u>G</u> G <u>A</u> ...R <u>P</u> S <u>L</u> A <u>S</u> A <u>L</u> A <u>C</u> V <u>I</u> L <u>I</u> F <u>T</u> V <u>D</u> I <u>G</u> N <u>L</u> L <u>V</u> I <u>L</u> S <u>V</u> R <u>N</u> K <u>L</u> R <u>N</u> A <u>G</u> N <u>I</u> F <u>V</u> S <u>L</u> A <u>V</u> D <u>L</u> V <u>V</u> A <u>V</u> P <u>Y</u> <u>P</u> <u>L</u> V <u>M</u> S <u>I</u> F <u>N</u> N <u>G</u> W <u>L</u>	
Xenopus	M <u>M</u> E <u>V</u> N <u>S</u> I <u>T</u> C <u>L</u> D <u>C</u> R <u>P</u> T <u>I</u> R <u>T</u> E <u>Q</u> D <u>A</u> Q <u>S</u> A <u>S</u> G.....L <u>T</u> S <u>L</u> A <u>V</u> L <u>I</u> F <u>T</u> I <u>V</u> V <u>D</u> V <u>L</u> G <u>N</u> I <u>L</u> V <u>I</u> L <u>S</u> V <u>R</u> N <u>K</u> L <u>Q</u> N <u>A</u> G <u>N</u> L <u>F</u> V <u>V</u> S <u>L</u> I <u>A</u> D <u>L</u> V <u>V</u> A <u>V</u> P <u>Y</u> <u>P</u> <u>V</u> I <u>L</u> I <u>A</u> I <u>F</u> Q <u>N</u> G <u>W</u> L	
Consensus	-----AL--V <u>L</u> I--T--V <u>D</u> --G <u>N</u> --L <u>V</u> I <u>L</u> S <u>V</u> --R <u>N</u> --K <u>L</u> --N <u>G</u> N <u>F</u> --V <u>S</u> L--A <u>D</u> L--V <u>A</u> --Y <u>P</u> P--L--I <u>F</u> --G <u>W</u> -L	
	III	IV
Human 1b	GE <u>H</u> C <u>K</u> A <u>S</u> A <u>F</u> V <u>M</u> G <u>L</u> S <u>V</u> I <u>C</u> S <u>V</u> F <u>N</u> I <u>T</u> A <u>I</u> A <u>I</u> N <u>R</u> C <u>Y</u> I <u>C</u> H <u>S</u> M <u>A</u> Y <u>H</u> R <u>I</u> Y <u>R</u> W <u>H</u> T <u>P</u> L <u>H</u> I <u>C</u> I <u>L</u> W <u>L</u> T <u>V</u> A <u>L</u> L <u>P</u> N <u>F</u> F <u>V</u> G <u>S</u> L <u>E</u> Y <u>D</u> P <u>R</u> I <u>S</u> C <u>T</u> F <u>I</u> Q <u>T</u> A <u>S</u> T <u>O</u> T <u>Y</u> T <u>A</u> V <u>V</u> V <u>I</u> H <u>F</u> L <u>P</u> I <u>A</u> V <u>V</u> S <u>C</u>	
Human 1a	G <u>Y</u> L <u>H</u> C <u>Q</u> V <u>S</u> G <u>F</u> L <u>M</u> G <u>L</u> S <u>V</u> I <u>C</u> S <u>I</u> F <u>N</u> I <u>T</u> G <u>I</u> A <u>I</u> N <u>R</u> C <u>Y</u> I <u>C</u> H <u>S</u> L <u>K</u> D <u>K</u> L <u>Y</u> S <u>S</u> K <u>N</u> S <u>C</u> V <u>L</u> L <u>I</u> W <u>L</u> T <u>L</u> A <u>V</u> P <u>L</u> N <u>R</u> G <u>T</u> L <u>Q</u> Y <u>D</u> P <u>R</u> I <u>S</u> C <u>T</u> F <u>A</u> Q <u>S</u> V <u>S</u> S <u>A</u> T <u>L</u> A <u>V</u> V <u>F</u> H <u>F</u> L <u>P</u> V <u>M</u> I <u>I</u> V <u>I</u> C	
Xenopus	G <u>M</u> H <u>C</u> Q <u>I</u> S <u>G</u> F <u>L</u> M <u>G</u> L <u>S</u> V <u>I</u> C <u>S</u> V <u>F</u> N <u>I</u> T <u>A</u> I <u>A</u> I <u>N<u>R</u>C<u>Y</u>I<u>C</u>H<u>S</u>L<u>R</u>Y<u>D</u>K<u>L</u>Y<u>N</u>Q<u>R</u>S<u>T</u>W<u>C</u>Y<u>G</u>L<u>T</u>W<u>I</u>L<u>T</u>I<u>I</u>A<u>V</u>P<u>N</u>F<u>V</u>G<u>S</u>L<u>Q</u>Y<u>D</u>P<u>R</u>I<u>S</u>C<u>T</u>F<u>A</u>Q<u>T</u>V<u>S</u>S<u>T</u>T<u>I</u>T<u>V</u>V<u>V</u>M<u>F</u>P<u>V</u>P<u>L</u>S<u>V</u>T<u>F</u>C</u>	
Consensus	G--H <u>C</u> --S--F--M <u>G</u> L <u>S</u> V <u>I</u> G <u>S</u> --F <u>N</u> I <u>T</u> --I <u>A</u> I <u>N<u>R</u>C<u>Y</u>I<u>C</u>H<u>S</u>--Y-----L--W--L<u>T</u>--A--P<u>N</u>--G--L--Y<u>D</u>P<u>R</u>I<u>S</u>C<u>T</u>F<u>Q</u>--S--Y<u>T</u>--V<u>V</u>V--H<u>F</u>--P---V--F<u>C</u></u>	
	VI	VII
Human 1b	Y <u>L</u> R <u>I</u> W <u>L</u> V <u>L</u> Q <u>A</u> R <u>R</u> K <u>A</u> P <u>E</u> S <u>R</u> L <u>C</u> L <u>K</u> P <u>S</u> L <u>R</u> S <u>L</u> T <u>H</u> F <u>V</u> V <u>F</u> V <u>I</u> A <u>C</u> W <u>A</u> P <u>L</u> N <u>C</u> I <u>G</u> L <u>A</u> V <u>A</u> I <u>N</u> P <u>Q</u> E <u>M</u> P <u>Q</u> I <u>P</u> E <u>G</u> L <u>F</u> V <u>T</u> S <u>Y</u> L <u>L</u> A <u>F</u> N <u>S</u> C <u>L</u> N <u>A</u> I <u>V</u> G <u>I</u> L <u>N</u> Q <u>N</u> F <u>R</u> E <u>Y</u> K <u>R</u> I <u>L</u> L <u>W</u> N <u>P</u> R	
Human 1a	Y <u>L</u> R <u>I</u> W <u>L</u> V <u>L</u> Q <u>V</u> R <u>Q</u> V <u>K</u> P <u>D</u> R <u>K</u> P <u>L</u> K <u>P</u> Q <u>D</u> F <u>R</u> N <u>F</u> T <u>H</u> F <u>V</u> V <u>F</u> V <u>I</u> A <u>C</u> W <u>A</u> P <u>L</u> N <u>C</u> I <u>G</u> L <u>A</u> V <u>A</u> I <u>N</u> P <u>Q</u> E <u>M</u> P <u>Q</u> I <u>P</u> E <u>G</u> L <u>F</u> V <u>T</u> S <u>Y</u> L <u>L</u> A <u>F</u> N <u>S</u> C <u>L</u> N <u>A</u> I <u>V</u> G <u>I</u> L <u>N</u> Q <u>N</u> F <u>R</u> E <u>Y</u> K <u>R</u> I <u>L</u> L <u>W</u> N <u>P</u> R	
Xenopus	Y <u>L</u> R <u>I</u> W <u>L</u> V <u>L</u> Q <u>V</u> K <u>H</u> R <u>V</u> R <u>Q</u> D <u>F</u> K <u>Q</u> L <u>T</u> Q <u>D</u> L <u>R</u> N <u>L</u> T <u>H</u> F <u>V</u> V <u>F</u> V <u>I</u> A <u>C</u> W <u>A</u> P <u>L</u> N <u>C</u> I <u>G</u> L <u>A</u> V <u>A</u> I <u>N</u> P <u>Q</u> E <u>M</u> P <u>Q</u> I <u>P</u> E <u>G</u> L <u>F</u> V <u>T</u> S <u>Y</u> L <u>L</u> A <u>F</u> N <u>S</u> C <u>L</u> N <u>A</u> I <u>V</u> G <u>I</u> L <u>N</u> Q <u>N</u> F <u>R</u> E <u>Y</u> K <u>R</u> I <u>L</u> L <u>W</u> N <u>P</u> R	
Consensus	Y <u>L</u> R <u>I</u> W <u>-</u> L <u>V</u> -Q-----L---D--R--F--T <u>H</u> F <u>V</u> V <u>F</u> V <u>L</u> F <u>A</u> -C <u>W</u> A <u>P</u> L <u>N</u> -I <u>G</u> L <u>A</u> V <u>A</u> --P----P--I <u>P</u> E--L <u>F</u> V--S <u>Y</u> --A <u>F</u> N <u>S</u> C <u>L</u> N <u>A</u> --Y <u>G</u> -L <u>N</u> Q <u>N</u> F <u>R</u> -E <u>Y</u> -R <u>I</u> --L---R	
Human 1b	H <u>C</u> I <u>Q</u> D <u>A</u> S <u>G</u> K <u>U</u> H <u>E</u> G <u>L</u> Q <u>S</u> P <u>A</u> P <u>P</u> I <u>I</u> G <u>V</u> Q <u>H</u> Q <u>D</u> A <u>L</u> 362 (SEQ ID NO:16)	
Human 1a	V <u>F</u> F <u>V</u> U <u>S</u> S <u>N</u> D <u>V</u> A <u>D</u> R <u>V</u> K <u>W</u> K <u>P</u> S <u>P</u> L <u>M</u> T <u>N</u> N <u>V</u> V <u>K</u> V <u>D</u> S <u>V</u> 350 (SEQ ID NO:12)	
Xenopus	L <u>L</u> F <u>L</u> D <u>T</u> S <u>R</u> G <u>T</u> E <u>G</u> L <u>K</u> S <u>K</u> P <u>S</u> A <u>V</u> T <u>N</u> N <u>Q</u> A <u>D</u> u <u>L</u> G <u>E</u> A <u>R</u> S <u>L</u> W <u>L</u> S <u>R</u> R <u>N</u> G <u>A</u> M <u>V</u> I <u>I</u> R <u>P</u> R <u>K</u> A <u>Q</u> I <u>I</u> H <u>Q</u> I <u>E</u> W <u>P</u> Q <u>S</u> S <u>W</u> A <u>T</u> C <u>R</u> Q <u>D</u> T <u>K</u> I <u>G</u> E <u>D</u> G <u>C</u> R <u>E</u> L <u>C</u> D <u>G</u> I <u>S</u> R 420	
Consensus	----D-S-----P-P----- (SEQ ID NO:2)	

Fig. 19




Fig. 20




Fig. 21




Fig. 22





Fig. 23



COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF, the specification of which

- is attached hereto.
- was filed on _____ as Application Serial No. _____
and was amended on _____.
- was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. SERIAL NO.	FILING DATE	STATUS
08/319,887	October 7, 1994	<input checked="" type="checkbox"/> Pending <input type="checkbox"/> Issued <input type="checkbox"/> Abandoned
08/261,857	June 17, 1994	<input checked="" type="checkbox"/> Pending <input type="checkbox"/> Issued <input type="checkbox"/> Abandoned

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162; William E. Booth, Reg. No. 28,933; Karl Bozicevic, Reg. No. 28,807; Barry E. Bretschneider, Reg. No. 28,055; Deirdre L. Conley, Reg. No. 36,487; Peter J. Devlin, Reg. No. 31,753; Valeta Gregg-Emery, Reg. No. 35,127; Willis M. Ertman, Reg. No. 18,658; David L. Feigenbaum, Reg. No. 30,378; Carol L. Francis, Reg. No. 36,513; Janis K. Fraser, Reg. No., 34,819; John W. Freeman, Reg. No. 29,066; Timothy A. French, Reg. No. 30,175; Alan H. Gordon, Reg. No. 26,168; Scott C. Harris, Reg. No. 32,030; Mark J. Hebert, Reg. No., 31,766; Gilbert H. Hennessey, Reg. No. 25,759; Charles Hieken, Reg. No. 18,411; Robert E. Hillman, Reg. No. 22,837; G. Roger Lee, Reg. No. 28,963; Steven E. Lipman, Reg. No. 30,011; Gregory A. Madera, Reg. No. 28,878; Ralph A. Mittelberger, Reg. No. 33,195; Ronald E. Myrick, Reg. No. 26,315; Robert C. Nabinger, Reg. No., 33,431; Frank P. Porcelli, Reg. No. 27,374; Eric L. Prahl, Reg. No. 32,590; Alan D. Rosenthal, Reg. No. 27,833; Richard M. Sharkansky, Reg. No. 25,800; John M. Skenyon, Reg. No. 27,468; Michael O. Sutton, Reg. No. 26,675; Rene D. Tegtmeyer, Reg. No. 33,567; Hans R. Troesch, Reg. No. 36,950; John N. Williams, Reg. No. 18,948; Gary A. Walpert, Reg. No. 26,098; Dorothy P. Whelan, Reg. No., 33,814; and Charles C. Winchester, Reg. No. 21,040.

Address all telephone calls to Paul T. Clark at telephone number 617/542-5070.

Address all correspondence to Paul T. Clark, Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804.

COMBINED DECLARATION AND POWER OF ATTORNEYCONTINUED

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Steven M. Reppert

Inventor's Signature: _____ Date: _____

Residence Address: Newton, MA 02166

Citizen of: United States of America

Post Office Address: 34 Day Street, Newton, MA 02166

25251.P11

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled HIGH-AFFINITY MELATONIN RECEPTORS AND USES THEREOF, the specification of which

is attached hereto.

was filed on June 6, 1995 as Application Serial No. 08/466,103

and was amended on _____.

was described and claimed in PCT International Application No. _____
filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. SERIAL NO.	FILING DATE	STATUS
08/319,887	October 7, 1994	<input checked="" type="checkbox"/> Pending <input type="checkbox"/> Issued <input type="checkbox"/> Abandoned
08/261,857	June 17, 1994	<input checked="" type="checkbox"/> Pending <input type="checkbox"/> Issued <input type="checkbox"/> Abandoned

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, William E. Booth, Reg. No. 28,933; Karl Bozicevic, Reg. No. 28,807; Barry E. Bretschneider, Reg. No. 28,055; Deirdre L. Conley, Reg. No. 36,487; Peter J. Devlin, Reg. No. 31,753; Valeta Gregg-Emery, Reg. No. 35,127; Willis M. Ertman, Reg. No. 18,658; David L. Feigenbaum, Reg. No. 30,378; Carol L. Francis, Reg. No. 36,513; Janis K. Fraser, Reg. No., 34,819; John W. Freeman, Reg. No. 29,066; Timothy A. French, Reg. No. 30,175; Alan H. Gordon, Reg. No. 26,168; Scott C. Harris, Reg. No. 32,030; Mark J. Hebert, Reg. No., 31,766; Gilbert H. Hennessey, Reg. No. 25,759; Charles Hieken, Reg. No. 18,411; Robert E. Hillman, Reg. No. 22,837; G. Roger Lee, Reg. No. 28,963; Steven E. Lipman, Reg. No. 30,011; Gregory A. Madera, Reg. No. 28,878; Ralph A. Mittelberger, Reg. No. 33,195; Ronald E. Myrick, Reg. No. 26,315; Robert C. Nabinger, Reg. No., 33,431; Frank P. Porcelli, Reg. No. 27,374; Eric L. Prahl, Reg. No. 32,590; Alan D. Rosenthal, Reg. No. 27,833; Richard M. Sharkansky, Reg. No. 25,800; John M. Skenyon, Reg. No. 27,468; Michael O. Sutton, Reg. No. 26,675; Rene D. Tegtmeyer, Reg. No. 33,567; Hans R. Troesch, Reg. No. 36,950; John N. Williams, Reg. No. 18,948; Gary A. Walpert, Reg. No. 26,098; Dorothy P. Whelan, Reg. No., 33,814; and Charles C. Winchester, Reg. No. 21,040.

Address all telephone calls to Paul T. Clark at telephone number 617/542-5070.

Address all correspondence to Paul T. Clark, Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804.

COMBINED DECLARATION AND POWER OF ATTORNEY CONTINUED

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: STEVEN M. REPPERT

Inventor's Signature: Steven Reppert Date: Aug 31, 1995

Residence Address: NEWTON, MA 02166

Citizen of: UNITED STATES OF AMERICA

Post Office Address: 34 DAY STREET, NEWTON, MA 02166

Full Name of Inventor: TAKASHI EBISAWA

Inventor's Signature: Takashi Ebisawa Date: September 25, 1995

Residence Address: TOKYO, JAPAN

Citizen of: JAPAN

Post Office Address: 1-1005 GARDEN HEIGHTS, KODAIRA, 1-445-1, OGAWA-CHO, KODAIRA-SHI,
TOKYO 187, JAPAN

25251.P11